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Tissue traumas are often prone to complications such as haemorrhages and 
inflammation, which can hinder healing. The challenge is to develop a system that 
curbs these problems by providing haemostatic and localized controlled antimicrobial 
effects. The strategy developed in this study involves using a haemostatic fused 
deposition modeled (FDM)-formed mesh composed of Polycaprolactone (PCL) and 
20wt% tricalcium phosphate (TCP), loaded with a model antimicrobial drug, 
gentamicin sulfate (GS; 15wt%), that will be released within a short duration to inhibit 
bacterial activity without affecting subsequent tissue regeneration. This platform 
technology can be applied to a variety of applications requiring interventions of 
haemostasis and drug elution. 
 
A series of in vitro and in vivo experiments were conducted to optimize and 
characterize this drug eluting haemostatic mesh’s drug eluting and haemostatic aspect. 
Haemostatic effect was preliminarily evaluated through optimizing the FDM-formed 
PCL-TCP mesh (85% porosity, 1mm thickness) for blood absorption.  
 
PCL was observed to promote platelet adhesion and activation, more prominently than 
glass positive control. Although in terms of contact activation, PCL performed poorer 
than glass, it was still regarded as a relevant haemostat as it showed significant 
haemostatic properties comparing to negative control.  
 
Upon adding TCP, both surface chemistry and topography were altered. To isolate 
surface topography effect, experimentations on gold sputtered specimens showed a 
decrease in platelet adhesion with increased surface roughness due to increasing TCP 
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Summary 
incorporation (0-25wt%). When evaluated with surface chemistry effect, it yielded a 
general increase in platelet coverage with increasing TCP content. In the balance of the 
two aspects, PCL with 20wt% TCP was selected for its optimal platelet adhesion.  
 
Architectural influence to haemostasis was also studied by comparing micro-scaled 
(FDM), sub-micron (nanofibers) and macro-scaled (film) architectures. It was shown 
that FDM-formed PCL structures had comparable blood contact activation and platelet 
adhesion to glass, justifying its use for this system.  
 
For the antimicrobial aspect, the incorporation of GS was optimised. 15wt% GS 
incorporation rendered most efficient even with bacterial reinoculations. 93% of total 
GS was released within 168 hours and was found to be non-cytotoxic to human dermal 
fibroblast. The burst release can be attributed to the hydrophilic surfaces caused by 
high TCP content in the FDM-formed mesh, with direct relation found between GS 
release rate and TCP content. Therefore, TCP content of 20wt% was once again 
chosen for optimum GS release during the critical infectious period while allowing 
subsequent tissue regeneration.  
 
When tested against gauze using an infected full-thickness wound mice model, the 
mesh eliminated the bacteria in wound effectively with no observable signs of overall 
infection after 7 days, led to excellent wound healing with 94.2% reduction in wound 
area by day 14 and stimulated faster wound healing as indicated from the improved 
neo-collagen deposition and re-epithelisation.  
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Summary 
In conclusion, the drug eluting haemostatic mesh was successfully developed using 
FDM technique. Besides haemostatic potential, this mesh was also showed to be an 
effective drug delivery platform for GS in both in vitro and in vivo environment and 
heal infected wounds more rapidly when compared to gauze.   
 
(Word count: 500) 
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Chapter 1 . Introduction 
1.1. General Background 
Tissue traumas arising from accidents or surgeries are susceptible to complications 
including uncontrolled bleeding (hemorrhage) and infections. Hemorrhages during 
implantations and in wounds occur rather frequently. It was also previously reported 
that uncontrolled hemorrhage remains the leading cause of pre-hospital trauma deaths 
[Kauvar et al. 2006, McManus et al. 2007].  Currently, there are many approaches 
adopted to bring about efficient haemostasis as will be discussed in the literature 
review. Very often, these approaches involving external interventions are often 
centered on certain key influential factors affecting haemostasis, which includes 
chemical cues, such as surface chemistry and chemotaxis of the material; and physical 
cues, such as the physical form, architecture and surface topography. With due 
considerations given to these factors, it was identified that the use of tricalcium 
phosphate (TCP) coupled with the fused deposition modeling (FDM) fabrication 
method as the chemical and physical aspects of interest respectively and investigate in 
depth the effects from these factors towards blood clotting.  
 
Infections of wounds following tissue trauma and surgery represent another major 
source of site morbidity, resulting in compromised clinical outcomes and increased 
mortality risks [Ragel and Vallet-Regi 2000]. Specifically in orthopaedic implant 
applications, 22% of revision operations arose due to implant infection [Achneck et al. 
2009], with consequent increased healthcare costs [Coello et al. 2005, Dreghorn and 
Hamblen 1989, Tunney et al. 1998]. Such infections are conventionally treated or 
prevented by systemic administration of antibiotics. However, such therapies are often 
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associated with the development of antibiotic resistant bacterial strains, as well as 
higher risks of systemic poisoning where large amounts of drugs are required to 
achieve efficacious concentrations at the infection site [Aronson et al. 2006, Murray et 
al. 2006, Selkon 1981]. Thus, the direct delivery of antibiotics to the infection site to 
maintain local drug concentrations at minimal inhibitory concentration is considered to 
be a safer and more effective approach [Cornell et al. 1993, Ragel and Vallet-Regi 
2000, Shinto et al. 1992]. For example, directed antibiotic delivery is used to treat 
osteomyelitis, a prolonged inflammation of the bone that brings about destruction of 
bone tissues and vascular channels caused by pathogenic microorganisms [Garvin and 
Feschuk 2005, Lazzarini et al. 2004]. Alternatively, direct delivery of antibiotics is 
also beneficial for other purposes such as wound dressings, where lower 
concentrations of antibiotics needs to be given as compared to systemic administration, 
which usually involves excessive doses to achieve substantial local effects.  
 
In light of these considerations, a haemostatic mesh, also capable of serving as a 
platform for on-site anti-microbial effects in an optimal elution manner. It was 
envisioned that this drug-eluting haemostatic mesh can be applied in various 
biomedical applications, including tissue engineering scaffold, surgical patch and 
wound dressing. This report details the development of a composite based on 
polycaprolactone (PCL) integrated with TCP, producing a PCL-TCP FDM-formed 
mesh architecture. The antimicrobial drugs will then be incorporated into the synthetic 
polymeric mesh for the localized release at wound or implant sites, with the TCP 
component and the general mesh FDM architecture to serve the haemostatic function.  
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1.2. Research aim and proposal outline 
The primary goal of this study was to develop and evaluate haemostatic PCL-TCP 
meshes for the delivery of antimicrobial drugs to wound or implant sites and sustain 
the elution concentrations above the minimum inhibitory concentration for a period of 
time. This was tested out in both in vitro and in vivo environments. To achieve this, the 
specific aims for this study were as follows: 
 
1. For the haemostatic aspect of the study: 
a. To ascertain the configuration and architecture of the mesh with the best 
blood absorption capacity for use throughout this work  
 
b. To study the haemostatic effect of PCL before and after the 
incorporation of TCP 
 
Hypothesis: With the incorporation of TCP into the PCL mesh, 
haemostatic properties will be improved. 
 
c. To study the effect of different scale of mesh architecture (nano, micro 
and macro) on blood clotting 
 
Hypothesis: Meshes with micro-scaled topographies, which are in the 
similar dimensional range as platelets, have improved haemostatic 
properties. 
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2.  For the antimicrobial aspect of the study: 
a. To evaluate the antimicrobial elution profile and its efficacy to 
eliminate bacteria over time and with repeated inoculation of bacteria 
while monitoring its cytotoxic effect 
 
Hypothesis: The incorporated model drug, gentamicin sulfate, will be 
eluted over the critical infectious period and retain its efficacy with 
repeated inoculations of bacteria. The eluted amounts of gentamicin 
sulfate are also hypothesized to be non-cytotoxic. 
 
b. To evaluate the effect of TCP incorporation in platform mesh on drug 
elution 
 
Hypothesis: With the addition of TCP, the rate of release of drug will 
be increased over a period of time due to the lowering of 
hydrophobicity of the platform mesh.    
 
 
c. To demonstrate that the antimicrobial incorporated mesh is capable of 
controlling infection in an animal wound model and consequently 
accelerate healing 
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1.3. Scope of Dissertation 
The thesis is composed of seven chapters and organized as follows: 
Chapter 1 gives the introduction to the field of research and the specific research 
objectives, aims and hypotheses.  
 
Chapter 2 provides the general background on the haemostasis, blood coagulation 
cascade and the current approaches utilized for haemostasis. The literature review on 
drug elution and its relation to mesh surface area are also highlighted. Background 
information on various materials used and their fabrication methods are also included. 
 
Chapter 3 illustrates the different mesh fabrication method in detail and justifies the 
choice of mesh configuration used throughout the research.  
 
Chapter 4 is on the haemostatic properties of the mesh, individual component material 
and the influence of mesh architecture on the blood clotting using various assays.  
 
Chapter 5 is on various antibacterial analyses done to evaluate the elution profile, 
antimicrobial efficacy and cytotoxicity of the various concentrations of GS 
incorporated. The influence of TCP incorporation and surface area to volume ratio of 
platform mesh on drug elution was also investigated. 
 
Chapter 6 is on the in vivo study done on infected full thickness excisional mouse 
model.  Characterization on the state of infection, tissue regeneration and wound 
healing at different time points are shown.  
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Chapter 7 provides the recommendations for future works and concludes the research 
work for this thesis.  
  
1.4. Project Flow Chart 
 
Figure 1-1. Overview flow chart of various stages covered in this study. 
C
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Chapter 2 . Literature Review 
2.1. Introduction 
It is vital to understand the mechanism of blood clotting and drug elution so as to apply 
a feasible methodology for implementation in this project. An in-depth understanding 
and knowledge of the different materials and fabrication methods are also vital in 
selecting the appropriate ones for our application. Finally, the principles of 
biomaterials engineering and the status of the current drug eluting and haemostatic 
meshes and technologies are reviewed in this chapter.  
 
2.2. Haemostasis and blood coagulation 
In common cases, bleeding occur once there is a disruption of blood vessels and 
without the timely arrest of the bleeding, hemorrhage and large volume of blood loss 
can take place and cause mortality. Haemostasis, which refers to the clotting of blood 
at an injury site, is a vital process which needs to be fully understood before devising 
any strategy to enhance it.  
 
Haemostasis consists of two major processes: coagulation and the formation of fibrin 
clot as shown in Figure 2-1  [Hanson and Harker 1996]. Coagulation can be achieved 
via activation of the intrinsic pathway or the extrinsic pathway. The intrinsic pathway 
is initiated by contact with surfaces for zymogen activation, including exposed 
collagen surfaces on damaged blood vessels, or by trauma to the blood itself [Schmaier 
1997].  
 
Chapter 2: Literature Review 
 
 Page | 11 
For the intrinsic pathway, Factor XII is being activated by absorption and it converts 
prekallikrein into kallikrein and with high molecular weight kininogen as a cofactor, 
Factor XI is being activated. The activated Factor XI and calcium ions then act 
enzymatically on Factor IX to activate it. Together with the activated Factor VIII, 
platelet phospholipids, calcium ions and Factor III from injured platelets, the activated 
Factor IX eventually activates Factor X. It is to be noted that this step is not present in 
patients with deficiency in platelets and Factor VIII (ie. Hemophilia). It is the 
combination of activated Factor X, Factor V, tissue or platelets phospholipids and 
calcium ions that cleaves the prothrombin into thrombin.  
 
In contrast, the extrinsic pathway begins with the release of a combination of many 
tissue factors from the traumatized vascular walls, specifically the tissue membranes. 
The complex of tissue factors combine with calcium ions activates Factor VII, which 
in turn activates the Factor X. The activation of Factor X is the convergence point of 
both the pathways.  
 
Thereafter, the activated Factor X, works in tandem with calcium ions, Factor V and 
platelets phospholipids to cleave prothrombin into active thrombin, marking the start 
of the common pathway.  
 
After the convergence of the two pathways and aided by thrombin, they combine to 
form fibrin clot. This proceeds by the formation of fibrinogen molecules into fibrin 
polymer fibers. Thrombin is a weak proteolytic enzyme which only cleaves the four 
low-molecular weight peptides from each molecule of fibrinogen thus forming fibrin 
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monomers. The fibrin fibers then crosslink to form fibrin clot which is a stable 
polymer with the aid of thrombin, calcium ions and the thrombin activated-Factor XIII.   
   
 









Figure 2-1. Blood Coagulation Cascade 
 
 
As shown above in the coagulation cascade, calcium played a major role in proceeding 
the coagulation cascade and is necessary for the coagulation reaction [Quick and 
Stefanini 1948]. It was also reported that with the addition of calcium, an increase in 
the activity of factor VIIa was observed [Bom and Bertina 1990]. It can also be 
observed from the figure that the rate limiting step in haemostasis is the production of 
thrombin from prothrombin. Therefore, the importance of calcium ions in the clotting 
cascade is once again highlighted as most of the activation processes requires 
sufficient calcium ions in the environment. This is one of the ideas which will be 
adopted in the design of the composite PCL-TCP mesh. Particularly, TCP has been 
identified as a potential haemostatic material, which will be further discussed in later 
Intrinsic System 
Factor XII→XIIa 
                     
           Factor XI→XIa 
                               







       Factor VII→VIIa 
 
Factor X                                                     Xa 
                                                                             Factor XIII 
  Prothrombin→Thrombin →                
                                                                                      XIIIa 


















Chapter 2: Literature Review 
 
 Page | 13 
sections of this chapter. To gain an in-depth understanding to the in vivo clotting 
mechanism of PCL-TCP scaffolds, in vitro contact activation, platelet interactions and 
whole blood responses were analyzed in this study.  
 
The combination of the three assays should ideally address the various aspects of the 
blood  clotting cascade [Ratner 2000]. These three aspects, thrombosis, coagulation 
and platelets, were also documented in the ISO standards for materials related blood 
clotting [ISO 2002]. However, the actual evaluation of blood clotting should only be 
conducted and measured for in vivo environment and the in vitro assays mentioned 
below will serve as an indication of potential capability.  
 
Thromboelastography (TEG) was carried out to study the extent of material-induced 
alteration to clotting kinetics in relation to contact activation of the clotting cascade. 
TEG was originally described in 1948 by Hartert and had since been widely used as a 
test to analyze haemostasis as a full process rather than isolating individual coagulation 
aspect [Whitten and Greilich 2000]. It basically induces and measures the strength of 
blood clot and the speed at which it is form under a low shear stress condition 
resembling that of venous blood flow [Wenker et al. 1997]. TEG also measures the 
whole blood response and has previously been shown to be more depictive even for in 
vivo responses [Lemm et al. 1980]. In comparison, partial thromboplastin time (PTT) 
test, another commonly used test for contact activation and common coagulation 
pathways, is not as sensitive to differences such as material-induced changes to the 
clotting kinetics [van Oeveren et al. 2002]. This insensitivity as observed by others was 
due to differences of plasma used for the assay [Prince et al. 1988]. 
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As mentioned earlier, platelets represent another vital component when evaluating 
blood clotting capabilities of the materials. In the in vivo setting, platelet attachment 
and activation played the role of stabilizing blood clot and proceeding of the 
coagulation cascade [Green 2006, Spijker et al. 2003]. Therefore, platelet adhesion and 
activation was incorporated in the collection of assays to be performed for the overall 
evaluation of blood clotting ability.  
 
In addition to the different aspects of clotting investigated by the different assays, 
blood being a complex tissue with many possible cross-talks across pathways, it will 
not be sufficient to just evaluate isolated components and aspects. Therefore, blood 
clotting index measurement using whole blood for the measurement of time required 
for formation of clot was included for a more holistic approach.  This approach 
involves the measurement of free floating erythrocytes in the remaining un-clotted 
blood through sampling at specific time points [Zhou and Yi 1999]. 
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2.3. Current advancements in haemostatic approaches 
2.3.1. Introduction 
Haemostasis has been a field present since ancient times. However, with the aid of 
biotechnology, it has made vast advancements in recent decades.  Various mechanisms 
to achieve haemostasis were used in many commercially available products and in this 
section, the different mechanisms explored will be reviewed.  
 
2.3.2. Occlusion of bleeding channels 
A common haemostatic approach applies the tamponade principle, or occlusion of the 
bleeding channels. Bone wax (Johnson and Johnson, Ethicon Inc, Somerville, NJ) and 
Ostene™ (Ceremed Inc, Los Angeles, CA) are two such products commonly used in 
controlling the bleeding in bone [Tan 2002, Wang et al. 2001]. However, as bone wax 
comprises a non-absorbable blend of materials, it has been reported to hinder bone 
healing, osteogenesis and increased risk of embolism after usage [Brightmore et al. 
1975, Howard and Kelley 1969, Robicsek et al. 1981]. Moreover, there were reports 
indicating impaired bacterial clearance in the wound site due to its nonabsorbability 
[Johnson and Fromm 1981, Katz and Rootman 1996].   
 
These disadvantages subsequently led to the development of Ostene™, an alkylene 
oxide copolymer that is hydrophilic and water soluble [Wang et al. 2001, Wellisz et al. 
2008]. It has been reported to heal and provide union to the sternum bone in 20 New 
Zealand white rabbits as compared to the fibrotic scarring and absence of bone tissue 
for the group treated with bone wax [Wellisz et al. 2008]. However, no publication on 
randomized controlled studies in humans was found to date.  
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2.3.3. Physical matrix for clot initiation 
Both gelatin foams (Pharamcia Corporation, Pfizer) and oxidized cellulose (Surgicel; 
Ethicon, Johnson and Johnson) helps to stop bleeding by providing a physical matrix 
for clot initiation. In addition, it  provides mechanical haemostatic action as the 
material swells upon application to the wound site [Wilkinson et al. 1981]. 
 
However, this mechanism also had problems as swelling of the agents often 
accompanied the haemostasis action. This could induce compressive forces when used 
in a confined space and cause complications when nerves were impinged [Wilkinson et 
al. 1981]. Reports have also shown that the oxidized cellulose agent, causes a decrease 
in the pH of the surrounding tissues and this could inactivate biological agents such as 
thrombin that the body produces naturally to aid in blood clotting [Tomizawa 2005]. 
Moreover, the risk of inflammations and delayed healing increased with low pH in 
wounds [Tomizawa 2005].  
 
2.3.4. Addition of coagulation cascade components 
Another common strategy introduces elements of the coagulation cascade, such as 
thrombin or fibrin, to enhance the speed of clotting. For example, thrombin purified 
from various natural sources such as bovine plasma was used (Thrombin-JM, marketed 
by King Pharmaceuticals, Inc).  However, significant immune responses following the 
usage on patients have been previously reported [Lawson et al. 2005, Schoenecker et al. 
2001].  
 
Fibrin sealants were have also been explored and used in patients [Rousou et al. 1989]. 
Fibrin sealant systems consist of both thrombin and fibrinogen that are mixed at site of 
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application. These remains effective even on heparanized patients and can thus be used 
in a wide variety of surgeries. However, before application, the sites have to be void of 
alcohols, iodines or heavy metal ions which are commonly present in antiseptics as 
these can denature the applied thrombin and fibrinogen.  
 
2.3.5. Platelet adhesion and activation 
It can be seen from the blood coagulation cascade (Figure 2-1) that platelet adhesion 
and activation is central to haemostasis. Microfibrillar collagen (MFC) takes advantage 
of this mechanism, and thus, many commercial products have been developed in 
different forms (powder, pressed sheets, sponge and pads) to achieve this mechanism 
(reviewed by Adneck et al) [Achneck et al. 2009]. Due to the large surface area 
provided by the MFC, platelets adhere to its fibrils, aggregate and initiate the thrombus 
formation process [Park et al. 2001, Park 1997]. Typically, haemostasis using this 
approach is highly efficacious, and arrest of  bleeding can be achieved within 5 
minutes [Achneck et al. 2009] However, the approach is limited by patients with 
platelet disorders [Abbott and Austen 1975]. It has also been reported that when excess 
MFC were left in vivo, it may bind to neural structures and bring about numbness or 
pain [Achneck et al. 2009]. 
 
The literature suggests that platelets represent an ideal target to induce blood clotting 
and arrest bleeding. Platelet behaviors in terms of adhesion and activation were thus 
closely monitored in this project. 
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2.3.6. Conclusion 
After reviewing the many different haemostatic strategies, we have chosen to study 
techniques targeting platelets to promote blood clotting for the development of the 
haemostatic mesh based on its unique merits and lack of in depth exploration. In 
general, all the current strategies used present different sets of advantages and 
disadvantages, thus the eventual usage of the products depends on the type of bleeding, 
mechanism of action and its interactions with the environment.  
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2.4. Drug Elution 
Accurate control delivery of bioactive factors and drugs to enhance and guide tissue 
regeneration for therapeutic purposes is an important requirement in advanced delivery 
platforms, tissue engineering scaffolds and biomaterials engineering [Biondi et al. 
2008]. Extensive studies have been conducted to date on the release kinetics of 
polymeric materials for drug delivery applications and was found to depend generally 
on the properties of polymers, drug characteristics and environmental conditions 
[Amass W 1998, Berni D.L 2006, Dittgen M 1997, Frank A 2001, Higuchi 1961, Jain 
2000, Li S 1996, Petropoulos J.H 1992, Siegel et al. 2006, Siepmann and Gopferich 
2001, Sung K.C 1998]. These polymer properties include hydrophilicity, 
bioresorbability and bioerodibility, degradation rates, swelling behavior and general 
permeability of the polymers, which will be discussed in the materials selection part of 
this chapter. Drug characteristics also affect the delivery mechanism, specifically the 
molecular weight of the drugs and its solubility. For instance, burst release effect have 
widely been associated with small molecular weight drugs as they are often soluble 
and can pass easily through the delivery structure [Huang and Brazel 2001].  
 
Drug release is based on two main types of release mechanisms, or a combination of 
them, namely diffusion and dissolution/degradation [Anse et al. 1995, Chien 1992, 
Park 1997, Rathbone et al. 2003, Robinson 1978, Saltzman 2001, Siegel et al. 2006]. 
Diffusion-controlled drug release mechanism works on the basis of either  
 
1. Drug release through rate-controlling membrane from a reservoir, resulting in 
zero-order release or 
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2. Through drugs dispersed in polymer matrix without a rate controlling barrier, 
resulting in a non-zero order of release. 
 
In the dissolution/degradation paradigm, drug release is dependent on the degradation 
or dissolution of the polymer matrix. For example, PCL is generally investigated for 
long term control release of drugs due to its slow degradation rate via bulk hydrolysis 
of its ester bonds [Dhanaraju et al. 2005, Leong et al. 2007, Perez 2001, Rathbone et al. 
2003, Sinha et al. 2004, Yang et al. 2001]. In most cases, drug delivery occurs as a 
combination of type 1 and type 2 diffusion mechanisms, whereby diffusion is 
accompanied by simultaneous polymer degradation.  
 
Surface area is a controlling factor for both type 1 and type 2 delivery mechanisms, 
thus influencing the rate of drug release. Previous studies have shown that an increase 
in the surface area to volume ratio (SA: VR) of a bioresorbable polymeric carrier 
resulted in an increase in the rate of drug delivery [Chawla and Amiji 2002]. The 
surface area of the drug delivery scaffold can be controlled by its architecture as in this 
thesis; comparison was done for different scaffolds with different SA:VR using 
different fabrication techniques, which will be in chapter 5. 
 
PCL, the material selected for the polymeric matrix of this study, has a relatively slow 
degradation rate, and the short term drug delivery mechanism prior to its degradation is 
largely diffusion-limited. It is therefore vital to control the fabrication parameters, such 
that the surface area of the drug eluting haemostatic mesh can be engineered for 
optimal type 1 release. Using micro-extrusion technology/FDM technology, the 
porosity of the drug delivery mesh can be controlled to vary surface area and 
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consequently the SA:VR. This relationship is clearly shown in Figure 2-2. One can 
then customize the rate of release based on the surface area by choosing a specific 
porosity for the delivery mesh. Using empirical analysis, PCL delivery meshes of 
similar dimension (50x50x0.5mm), the scaffold (50% porosity) fabricated using fused 
deposition modeling method with the laydown pattern of 00/900 is able to achieve a 
SA:VR of 7.94 as compared to 4.08 for a non-porous film fabricated by heat press or 
solvent casting method of similar thickness. The FDM-formed scaffolds have almost 
doubled the VR value. It is therefore expected that the rate of drug delivery is higher 
for FDM-formed scaffolds as compared to non-porous films. In conclusion, the 
architecture, specifically the SA of the drug delivery scaffold is a crucial criterion to be 
considered when engineering a specific rate of drug delivery. Consequently, the 
diffusion and degradation kinetics for a drug-polymer system can be designed to cater 
for the drug release profile desired.  
  
































Figure 2-2. Relationship for porosity of FDM-formed mesh against total surface area for drug 
delivery [Teoh et al. 2008] 
 
Chapter 2: Literature Review 
 
 Page | 22 
2.5. Biomaterials Engineering 
The overall success of using biomaterials for applications ranging from implants to 
medical devices often depends on various factors. These factors namely 
biocompatibility, host-tissue reaction to implants, cytotoxicity, sterilizability, 
functionability, manufacturability and structure-property relationships are viewed as 
general requirements for biomaterials [Black 1992, Dec et al. 2002, Greco 1994, Park 
J.B 1992, Park and Lake 1992, Ratner et al. 1996]. However, differing requirements 
may arise due to the applications and these could even be opposite occasionally. 
Therefore, understanding the science behind biomaterials engineering is vital due to 
the wide range of applications.  
 
Biocompatibility is one of the above mentioned factors with very high importance as a 
material must not induce host-tissue response upon implantation but promote good 
tissue-implant integration [Teoh 2004]. An initial burst of inflammatory response is 
acceptable but prolonged inflammation may signify incompatibility and bring about 
tissue necrosis. 
 
Sterilizability is also another vital material requirement for biomaterials applications. 
The material must be able to undergo sterilization before it can be implanted in vivo. 
With a wide variety of sterilization methods developed, such as gamma irradiation, gas 
(ethylene oxide) and steam autoclaving, many materials will then be able to be 
sterilized without damaging their inherent material properties (degrading it 
prematurely), or release toxic gases upon sterilization.  
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On top of these, manufacturability is vital to the success of the biomaterials usage. 
This is because, no matter how good a material, if it cannot be easily formed and made 
into the required shape/size for it to be used, then it cannot be utilized. Therefore in 
this thesis, a major contribution will be demonstrating an easy to fabricate drug 
delivery platform with additional haemostatic properties.  
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2.6. Materials selection 
The drug delivery platform with added haemostatic properties developed in this study 
comprises of three main materials, namely polycaprolactone (PCL), tricalcium 
phosphate (TCP) and the model drug Gentamicin sulfate (GS). 
 
2.6.1. Polycaprolactone 
Poly (ε-caprolactone) is a semi-crystalline linear aliphatic polyester that belongs to the 
family of poly (ω-hydroxy esters) and has the molecular repeating units of five non-
polar methylene groups (CH3) and a relatively polar ester group as shown in Figure 2-3 
[Kimura 1993]. PCL can be made by using ring opening method or addition 
polymerization using stannous 2-ethyl hexanoate or stannic chloride dehydrate as 
catalyst [D.E Perrin 1998]. 
 
 
Figure 2-3. Repeating unit of PCL 
 
 
It exhibits exceptionally low glass transition temperature of -600C, low melting 
temperature of 600C and high thermal stability with a decomposition temperatures of 
3500C. Due to its low glass transition temperature, PCL exists as a rubbery state at 
room temperature. Therefore it is one of the most flexible FDA approved biomedical 
polymers. These properties enable PCL to be easily processed via various fabrication 
methods that utilizes a slightly heated temperature, without significant molecular 
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weight loss [Hakkarainen 2002]. With the low glass transition temperature, fabrication 
of drug incorporated meshes could also be relatively easier.  
 
The mechanical properties of PCL is also an advantage as it has been reported to have 
a tensile strength of 16MPa, tensile modulus of 400MPa and elongation at break at 
80%-1000% depending on its molecular weight [Engelberg and Kohn 1991, Sarasam 
and Madihally 2005]. This provides very good mechanical integrity for the composite 
mesh and it enables the user to handle easily.  
 
PCL is also known to degrade hydrolytically due to the hydrolysis susceptibility of its 
aliphatic ester linkages [Pitt et al. 1981]. In vivo, PCL was found to breakdown into ε-
hydroxy-caproic acid (C6H12O6) and then metabolized into carbon dioxide and water 
when exposed to tissue fluids [Coello et al. 2005, Pitt 1992, Pitt et al. 1979]. The rate 
of degradation of PCL can be controlled by its molecular weight, particle size and the 
surface area, whereby increasing the surface area increases its degradation rate. It is 
also noted that PCL degrades slower than those in the ester family due to its 
crystallinity. However, the rate of degradation can also be modified by many methods 
for example through altering its structure. Another of such method is through adding 
another material, such as TCP [Chen et al. 2000]. The controlled rate of degradation of 
the mesh would aid in reducing the risk of acidosis and also allows the retention of 
mechanical properties during remodeling/tissue growth [Rai et al. 2005].  
 
PCL is bioresorbable, obviating the need to remove the material and eliminating the 
risk of injuring the clotted wound surface, underlining the potential use in implant and 
wound dressing applications. Extensive in vitro and in vivo biocompatibility has shown 
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that the polymer and its degradation products are non-toxic to local and general body 
tissues [Hutmacher et al. 2001, Rutledge et al. 2003, Schantz et al. 2002]. This has 
resulted in the US Food and Drug administration approval of a number of medical and 
drug delivery devices [Bezwada et al. 1995, Schwope et al. 1977, Schwope et al. 1974]. 
PCL is presently regarded as a soft and hard tissue compatible bioresorbable material 
[Hutmacher et al. 2001]. 
 
Polymeric carriers have been studied extensively for the purpose of direct delivery of 
antibiotics with a wide range of applications ranging from tissue engineering scaffolds 
to topical wound dressings. The usage of biodegradable polymers as drug delivery 
platforms were regarded to be desirable as the system can be degraded and removed 
from the body naturally and without any adverse effects [Changez et al. 2004]. PCL is 
one such biodegradable polymer employed in a wide range of biomedical applications, 
which includes the Capronor implantable drug delivery system for sustained 
administration of hormonal contraceptives  [Chang et al. 2006]. The high permeability 
of PCL resulting from its rubbery characteristics is often also used for delivery of low 
molecular weight drugs such as steroids and vaccines [Benoit et al. 1999, Pitt et al. 
1979]. Our group had previously demonstrated the use of PCL-20%TCP as a delivery 
system for platelet-rich plasma and bone morphogenic protein-2 in vitro [Rai et al. 
2005, Rai et al. 2005]. However, its delivery of low-molecular weight hydrophilic 
antibiotics has not been explored. Also, when degraded in vitro, PCL-TCP scaffolds 
formed a nucleation of calcium-rich surface that was bioactive in nature [Y. Lei 2007]. 
This calcium-rich surface could possibly be a rich source of calcium ions and aid in the 
enhancement of blood clotting.  
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2.6.2. β-Tricalcium Phosphate 
Tricalcium phosphate (TCP) exists in four general forms, α, β, γ and super-α phases 
and has a chemical formula of Ca3(PO4)2 which is similar to the amorphous biologic 
precursors to bone [Famery R. 1994]. They are considered bioactive materials with the 
osteoconductive capability, able to bind directly to bone materials, non-cytotoxic, 
biocompatible and induce minimal immunologic and foreign body reactions [Bohner 
2000].  
 
TCP has been readily used in the field of orthopedic and dental applications due to the 
osteoconductive property [Laffargue et al. 1999, Orii et al. 2005]. However, the usage 
of TCP in the field of wound dressing and haemostatic applications have yet to be 
thoroughly explored.  As demonstrated in the earlier section, the presences of calcium 
ions are critical to the coagulation pathway. Calcium, for an instance, mediates the 
binding of the complexes via the terminal gamma-carboxy residues on factor Xa and 
factor IXa to the phospholipids surfaces [Brewer 2006]. It is also needed in the 
conversion of prothrombin to thrombin and fibrinogen monomer to fibrin fibers, which 
are the functional players for blood clotting. 
 
Thus, to aid the process of blood clotting, the strategy employed for our composite 
mesh is to combine the advantages of the microarchitecture from FDM-formed 
fabrication method and biochemical attraction of TCP to adhere and trap platelets, 
while providing calcium ions to aid the clotting process. It is therefore hypothesized 
that with the addition of TCP to the composite mesh, haemostatic action will be 
enhanced. 
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2.6.3. Gentamicin sulfate  
Gentamicin sulphate (GS), a widely used aminoglycoside with antibacterial activity 
against both aerobic gram-positive and gram-negative bacteria, was chosen as the 
model drug for incorporation. It is produced by various species of the genus 
Micromonospora and work by rapid binding to the bacterial ribosomes, specifically the 
30S ribosome, and therefore inhibit the protein synthesis and cause damage to the 
bacterial cell membrane [Spahn and Prescott 1996]. The disturption in the decoding 
function was known to be through a complex and multistep process [Kumar et al. 
2008]. 
 
GS generally cannot be administered orally or transdermally due to its poor intestinal 
and dermal permeability thus a good delivery method for GS will be topical 
administration by incorporating it in the mesh [Shiozuka et al. 2009]. Moreover, the 
general concern about risk of over toxicity and systemic toxicity can also be avoided 
when low amount incorporated can be released locally, targeting only the infection site 
[Griffis et al. 2009]. This antibiotic is also heat-stable, able to withstand up to 170°C 
during processing and thus can be easily processed using different methods of 
fabrication and incorporation including fused deposition [Khang et al. 2000]. 
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2.7. Fabrication process 
A number of fabrication processes were explored in this study. These were tested and 
used for the fabrication of different PCL-TCP meshes for comparisons throughout.  
 
2.7.1. Fused deposition modeling 
Fused deposition modeling (FDM) is the method employed to fabricate the 
antimicrobial incorporated PCL-TCP layer with a micro architecture. FDM is a type of 
rapid prototyping method which was invented by Crump SS of Stratasys Inc [Crump 
1992]. Basically, it involves the deposition and fusing of the various layers of polymer 
melt. The polymer is supplied to the machine either in the form of a filament or pellets, 
where the melting of the polymer will have to be done by the FDM machine in the 
heated chamber. Generally, rollers or screws will force the filament or molten polymer 
pellets through the heated chamber and out through the nozzle at the exit. At the nozzle, 
the molten microfilaments will be extruded and laid down on the collecting plate as the 
nozzle moves in a pre-programmed translation, as shown in Figure 2-2 [Hutmacher et 
al. 2001, Zein et al. 2002]. 
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Figure 2-4. Schematic of FDM extrusion and deposition process [Zein et al. 2002] 
 
FDM is computer controlled, highly reproducible and requires no post processing. It is 
capable of producing scaffolds/meshes with interconnected pores within the 
honeycomb-like structure and that increases the surface area to volume ratio for the 
possible absorbance of platelets, drugs and fluids. The porosity contributes to the 
potential haemostatic nature of the PCL-TCP composite layer with micro architecture 
as having micro-sized pores would function similarly to a platelets trap, which will be 
concentrated at the injury site.  
 
As compared to other fabrication methods, FDM does not require any solvent and 
offers flexibility and ease in operation, processing and material handling. Although it 
has been stated by the Stratasys Inc that the resolution of the FDM is limited by the 
nozzle size, which lies in the range of 254-406µm, it was noted that with the same 
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nozzle size, a variety of rod size in the micrometer range can be achieved for the 
fabrication of the mesh layer. This can possibly be done through a faster control of the 
line speed, which is the speed at which the deposition nozzle moves across the 
collecting plate so as to further reduce the deposited rod diameter. With a faster 
translation speed, the polymer to be deposited gets stretched and thins down in the 
direction of translation and thus forming a smaller rod size as compared to the original.  
 
Figure 2-5. PCL-TCP mesh layer 
 
 
2.7.2. Heat press film 
Polymer membranes were often thought to be favorable matrices for fields such as 
dermatology, ophthalmology and even vascular tissue engineering due to its thinness 
and having less material to minimize possible adverse host-tissue response. However, 
heat pressed films and solvent cast films alike, have low mechanical strength, as 
compared to other implant materials, such as PLLA and PGA fabricated in the similar 
fashion. Details on the fabrication set up will be discussed in chapter 3. 
 
Rod diameter / size 
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2.7.3. Electrospinning 
Electrospinning has recently emerged as a useful technology to produce fibrous textiles 
form polymer solutions [Deitzel et al. 2001, Fong and Reneker 2001, Huang et al. 
2003, X. Fang 1997]. It is able to produce fibers with diameters in the submicron to 
nanometer range mimicking the natural extracellular matrix deposited by cells [Jin et 
al. 2002]. A schematic overview of the electrospinning process is shown in Figure 2-6. 
Briefly, a constant supply of polymeric fluid is ejected from the end of the spinneret by 
a high electrostatic force generated by the voltage supplied, towards the grounded 
collector plate. The fiber that is drawn by the electrostatic force is deposited in a 
random fashion forming a nanofibrous mat. In electrospinning, many factors can be 
adjusted to generate mats with different geometries and structural properties such as 
shell-cored nanofibers, ultra-fine nanofibers and hollow nanofibers [Zhang et al. 2010]. 
These parameters include electric field strength, distance of electric field, length and 
radius of the spinneret, solution flow rate and solution parameters such as 
concentration, viscosity, ionic strength and conductivity [Huang et al. 2003]. Standard 
parameters have been determined for electrospinning various polymers, thus ensuring 
reproducibility and manufacturability. To date, more than 200 different types of 
polymer electrospinning have been reported [Bhardwaj and Kundu 2010]. This 
provides a large possibility of biocompatible materials for a more bioactive approach 
to tissue engineering [Huang et al. 2003]. However, in this study, PCL-TCP composite 
nanofibers were not successfully fabricated, thus for comparison of architectures, PCL 
nanofiber meshes and PCL FDM-formed meshes were used.  
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Chapter 3 . Polycaprolactone Construct Fabrication and 
Characterization 
3.1. Introduction 
Various constructs of different compositions and architectures were fabricated using 
PCL as the base material and compared in this study. These constructs were mainly 
fabricated using the three different fabrication methods namely FDM, heat pressed 
method and electrospinning, which will be applied in other chapters as well. 
Constructs obtained via the FDM method will be further optimized in this chapter for 
the optimal porosity and thickness suitable for the purpose of a drug-eluting 
haemostatic mesh. The optimal FDM-formed mesh configuration will then be 
compared with the other constructs in terms of their haemostatic and drug eluting 
capabilities in the subsequent chapters. 
 
3.2. Fused deposition modeling method 
PCL pellets of Mr of 80000 from Sigma Aldrich (Milwaukee, WI USA), medical grade 
beta Tricalcium Phosphate (TCP) and gentamicin sulfate (GS) powder (USP testing 
specifications) from Sigma Aldrich were used for the fabrication of meshes with 
varying compositions (detailed in Table 3-1). The TCP particles were noted to be of 
10µm in size.  
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Table 3-1. Table summarizing the different meshes fabricated and tested in the research using 
FDM 
 







PCL pellets were fed first between the sterile rollers of a two-roll mill heated to 800C, 
which softens and melts the polymer. After which, TCP and GS powders were then 
mixed evenly into melted PCL. This blend was then collected in a sterile manner and 
allowed to cool to room temperature. 
 
 
Figure 3-1. Addition of TCP and GS particles to PCL on two-roll mill machine. 
 
 
The composite blend was then extruded into filaments, and processed via fused 
deposition modeling to produce meshes with honeycomb-like pattern, interconnected 
TCP and GS 
PCL 
80°C 
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pores and controllable porosity. For the optimization study to select the FDM-formed 
mesh with optimal porosity and thickness, meshes of different porosity ranging from 
70% to 85% dimension of 50x50x1.5mm and 50x50x1mm and laydown pattern of 
00/600/1200 were used, which will be detailed in section 3.5 of this chapter.  
 
3.3. Heat press method 
Composite blends were produced as described above in Section 3.2, and subjected to 
constant melt pressing at 80°C, under a static pressure of 10MPa for the first 10 
minutes and increased to 28MPa for the next 10 minutes. As shown in Figure 3-2. The 
pressure of 28MPa was sustained after the heat press was left to cool overnight. A 
sheet of thickness between 0.1mm and 0.15mm was obtained using this method as 







Figure 3-2. Heat press of PCL-TCP-GS film 
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Figure 3-3. SEM micrograph of PCL heat pressed sheet at magnification of 70x, 
 
 
3.4. Electrospinning method 
Polycaprolactone was fabricated into nanofibrous mat using the electrospinning 
method. PCL pellets were first dissolved in a 7:3 dichloromethane: methanol mixture 
to produce a 7.5 wt% PCL and placed on a shaker at 100 rpm for 6 hours. Complete 
dissolution was observed. 
 
Subsequently, PCL solution was added to a 3ml syringe mounted on a syringe pump 
(KD Scientific) and delivered at a flow rate of 1.5 ml/h through a PTFE tubing 
(Spectra-Teknik) to a blunt-ended 21 Gauge syringe needle. A needle to collector 
distance of 15 cm was used. The DC field was induced by a high voltage supplier 
(Spellman CZE 1000) operated at 15 kV. Electrospinning was allowed to proceed for 
two hours to obtain films of thicknesses 10 – 20 μm. Samples were vacuum dried at 
30°C to remove all solvents prior to use. 
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3.5. Optimization of FDM-formed mesh 
The careful selection and combination of the various configurations for the FDM-
formed mesh is vital for effective clotting of blood and efficient delivery of drugs. In 
this section, a few of the most commonly used configurations (various porosity and 
thickness of mesh) were fabricated using the FDM-formed method and tested using 
blood absorption study to find an optimum configuration for future testing usage.  
 
Absorption test was conducted to determine the amount of blood the PCL-TCP mesh is 
able to absorb. With the material being able to absorb more blood and retain it, the 
chances and rate of clotting could be increased. On the other hand, if the material is 
able to absorb more blood plasma and water, the clotting factors could be aggregated 
and concentrated at the wound site thus promoting clotting [Barnard and Millner 2009].  
 
Therefore in this study, we analyze PCL-TCP mesh’s absorption on citrated blood. It is 
hypothesized that with the micro-sized rods of FDM-formed meshes, it will be able to 
attract platelets and induce faster clotting while providing the sufficient mechanical 
integrity for easy handling. 
 
3.5.1. Materials and Methods 
For the blood absorption study conducted, citrated porcine blood was collected for 
blood clotting experiments, as approved by the National University of Singapore 
Institutional Animal Care and Use Committee and Defence Science Organisation-
Institutional Animal Care and Use Committee. The anticoagulant used was 3.8 wt% 
sodium citrate with HEPES added in the concentration of 20 g to 1 litre of solution.  1 
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part of the anticoagulant was added and gently mixed with 9 parts of porcine blood 
drawn from a healthy pig.  
 
FDM-formed meshes with different configurations (PCL-TCP mesh with 70% porosity, 
1mm thick; 70% porosity, 1.5mm thick; 85% porosity, 1mm thick; 85% porosity, 
1.5mm thick) were evaluated for all the tests.  
 
The protocols were in adherence to the ASTM standards for fluid absorption. In brief, 
the specimens to be tested were cut into 0.8 x 0.8 cm squares with the cut edges 
smoothened. 5 pieces of the specimen were immersed in 1.5ml of citrated blood. The 
specimens were immersed in 24-well plates and incubated at 370C, humidified 
atmosphere for 2, 24 and 48 hours. At the time points, specimens were taken out, 
placed on a paper towel for 3 seconds and weighed immediately. The fluid uptake of 
the material can then be calculated from equations adapted from Freymiller et al. and 
Maquet et al. [Freymiller and Aghaloo 2004, Maquet et al. 2004]. 
 
Amount of fluid absorbed per unit volume = (Wwet – Wdry) / Volmesh 
Where  Wwet = weight of wet sample 
Wdry = weight of dry sample 
Volmesh = volume of FDM-formed mesh 
 
Data points in this portion are expressed as means ± standard deviations. Differences 
between the means were analyzed for statistical significance using Student’s unpaired 
t-test. P values <0.05 were considered to be significant. 
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3.5.2. Results and Discussions 
3.5.2.1. Gross morphology of FDM-formed meshes 
The gross observation of the PCL-TCP meshes fabricated with different porosity using 
the FDM method is as shown in the following Figure 3-5. It is observed that uniform 




Figure 3-4. Photograph of PCL-TCP with 15wt% GS (A): porosity 75%, (B): porosity 85% 
 
A B 
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3.5.2.2. Blood absorption study 
 
Figure 3-5. Blood absorption data (per unit volume) after immersion in citrated whole blood for 
various time points at 37oC. # indicates a statistical significance with all other specimens within 
the 24hr immersion period. * indicates a statistical significance between the 2 specimens. (p < 0.05) 
 
 
An overall increase in the amount of absorbed blood with increasing time for all the 
specimens was observed. Hence it was clear that the PCL-TCP material could attract 
and absorb blood components. Since the PCL-TCP material had good blood affinity, it 
could aid in clotting of blood by absorbing more blood and thus concentrating the 
clotting factors within the mesh. 
 
Amongst the PCL-TCP groups with different configurations, the PCL-TCP mesh at 
85% porosity and 1mm thickness was chosen as the mesh to be studied subsequently 
due to statistically higher amount of blood absorbed at all three time points. The 85% 
porosity mesh of 1mm thickness was also favorable due to it being physically more 
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pliable and therefore able to conform and be applied more easily to various curvatures 
when used as surgical patches or wound dressings.  
 
3.5.3. Conclusion 
In conclusion, the methods of fabrication for the FDM, heat-pressed and electrospun 
constructs have been described in this chapter. These constructs will be characterized 
and compared with respect to their haemostatic and drug eluting capabilities in the 
subsequent chapters. From the optimization study performed for the FDM-formed 
construct, PCL-TCP with the thickness of 1mm and porosity 85% was shown to be 
able to absorb significantly most amount of blood. With due consideration given to its 
ease of application and its absorption advantage, PCL-TCP of 1mm thickness and 
porosity 85% were to be used from this point on for subsequent comparative studies.  
.
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Chapter 4 . Haemostatic Properties 
4.1. Introduction 
The blood clotting aspect of PCL-TCP meshes were evaluated through a series of 
studies on different factors that can influence blood clotting. Firstly, the selection of 
materials could greatly influence the haemostatic properties of the mesh. Thus in this 
part of the study, the haemostatic properties of PCL and TCP were individually 
evaluated. To gain a more holistic and in-depth understanding, various assays such as 
the platelet adhesion (PA) study, whole blood clotting index (BCI) assay and 
thromboelastography (TEG) were carried out to determine the influence of various 
aspects on haemostasis. Specifically, the PA assay characterized platelet activity when 
platelet-rich plasma (PRP) was in contact with the material of study, while BCI looked 
at the amount of coagulated red blood cells upon blood clotting and TEG demonstrated 
the surface-induced contact activation of whole blood.  
 
Secondly, the architecture of the haemostatic mesh was also hypothesized to contribute 
significantly to the haemostatic properties. Architecture in this case refers to the 
meshes of the same composition (pure PCL) but of different structures in the nano, 
micro and macro scale.  Pure PCL was used in this part of the study to rule out other 
variables relating to TCP, such as the chemical effect and surface topographies 
rendered, as these were speculated to contribute towards blood clotting. 
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4.2. Influence of materials selection 
4.2.1. Influence of PCL on haemostatic properties 
The haemostatic influence of pure PCL was first evaluated using the PA and TEG 
assays. PCL heat pressed films were tested for its haemostatic ability together with 
glass cover slips using native citrated blood. Whole citrated blood contained in 
polypropylene centrifuge tubes served as negative control for each assay. Glass cover 
slip, on the other hand, served as a positive control as it is the ‘gold standard’ in 
relation to blood clotting assays. PCL heat pressed films were selected, instead of the 
FDM-formed structure, as they were deemed to be architecturally similar to that of 
glass cover slip and could thus provide an accurate comparison of the materials.   
 
4.2.1.1. Materials and methods 
For all the blood coagulation assays conducted in this analysis (PA and TEG), citrated 
human blood was collected as approved by the National University of Singapore 
Institutional Review Board. The anticoagulant used was 3.8wt% sodium citrate with 
HEPES added in the concentration of 20 g to 1 litre of solution.  1 part of the 
anticoagulant was added and gently mixed with 9 parts of human venial blood drawn 
from a healthy individual via a clean venepuncture from the antecubital vein using a 21 
gauge needle and syringes.  
 
Platelet adhesion assay 
For the PA assay, the PRP used was obtained by centrifuging anticoagulated blood at 
170 G for 10 min using centrifugal machine (Eppendorf 5804, Germany) [Tozum and 
Demiralp 2003]. A clear separation of PRP and the heavier components of blood, such 
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as erythrocytes, were then obtained. The platelet rich plasma was then pipetted out for 
testing. In general, approximately 6 ml of human PRP could be obtained from 25 ml of 
citrated human blood. The specimens to be tested (PCL film and glass cover slip 
[Marienfeld, Germany]) were first loaded with 20 µl of 0.2M calcium chloride (CaCl2) 
in 24-well plates to compensate for the calcium ions in blood bounded by the 
anticoagulant and initiate clotting upon contact with plasma. All the specimens tested 
in this assay were of 12mm diameter and of similar gross area. 400 µl of human blood 
plasma was then pipetted into each well, ensuring complete immersion of the samples. 
The immersed samples were then incubated at 370C for 60mins.  
 
Preparation of samples for SEM 
After incubation, the samples were then rinsed in deionised water thrice before fixing 
in 500 µl of 4% formaldehyde for 30 min. The samples were then observed using 
scanning electron microscopy (SEM). The fixed samples were dehydrated for 10 min 
through each graded ethanol series of 30%, 50%, 70%, 90% and 100%. They were 
then taken out for air drying prior to gold coating using JEOL JFC-1200 fine coater 
under high vacuum. The specimens were gold sputtered at 10 mA, pressure of 10 Pa 
for 60 s. At least 5 micrographs of 500x magnification were taken with the SEM 
machine at different locations on the specimen tested. SEM pictures of higher 
magnification were also taken to evaluate the platelet morphology that served as an 
indication of its level of activation in accordance to Ko and Cooper as shown in Figure 
4-1 [Ko and Cooper 1993].  
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Figure 4-1. The stages and morphology description of platelet activation for the detection of extent 
in activation of adhered platelets [Ko and Cooper 1993]. 
 
Thromboelastography 
For TEG, an adapted TEG protocol was used [Chevallier et al. 2005]. The specimens 
to be tested (PCL film and glass cover slip) were incubated with 500µl of citrated 
whole blood for 30min at 370C. 340µl of blood from each specimen were then 
retrieved and transferred to a disposable cuvette in the computerized TEG 5000 
Hemostasis Analyzer (Haemoscope Corp., USA) with 20 µl of 0.2 M of CaCl2 to 
initiate the blood coagulation process. Cigar shaped TEG plots of relative clot strength 
versus time (as shown in Figure 4-2) were generated and recorded using a data logger.  
 
Chapter 4: Haemostatic Properties 
 
 Page | 49 
 
 
Various parameters were obtained as a measure of clotting kinetics (as shown in Table 
4-1) [Hall et al. 1989].  
 
Table 4-1. Parameter for TEG 
Parameters Symbol Representation 
Reaction time r Period of time of latency from the time that the blood was 
placed in the cTEG until initial fibrin formation 
Clotting time  k Time required to arrive at a defined level of clot strength. 
(time taken for the clot to reach 20% of maximum strength) 
Angle A Measure of rapidity of fibrin build-up and cross-linking 
Maximum 
amplitude 
MA Ultimate strength of the fibrin clot as an indication of 
surface consumption of clotting proteins 
 
Blood clotting index assay 
BCI assay provides an indication of the blood clotting time required in specific relation 
to the red blood cells participating in the clotting. For this assay, the specimens were to 
be placed into flat-bottom bottles thermostated in water bath at 37°C for 5 minutes. 0.3 





Figure 4-2. Schematic representation of TEG plot and 
derivation of the parameters. 
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the surface until slowly covered. The bottles were then incubated at 37°C. After fixed 
time points of 2, 5, 10, 15 min from the start, 10 ml of deionised water was added by 
dripping down the walls of the bottle, taking special care not to disturb the blood clot. 
After which 10 ml of the solution was removed and centrifuged at 100 G for 30s. The 
supernatant was then to be decanted and after the addition of 40ml of deionised water, 
kept in 37°C for 60 min.  The relative absorbance of blood samples which had been 
diluted to 50ml was then analyzed using spectrophotometric measurements at 542nm. 
The reference value of 100 was assumed to be that of absorbance of 0.25ml citrated 
blood in 50 ml deionised water at 542 nm. The BCI of the different specimens at 
different time points could be quantified by the following equation: 
 
BCI = 100x (abs of blood which had been in contact with sample at 542nm) 
Abs of citrated blood in water at 542nm 
 
 
Data points in this portion are expressed as means ± standard deviations. Differences 
between the means were analyzed for statistical significance using Student’s unpaired 
t-test or one-way ANOVA with post hoc Scheffe test . P values <0.05 were considered 
to be significant. 
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4.2.1.2. Results for platelet adhesion 
 
 
Figure 4-3. SEM micrographs of A) Glass slide after 60 min of immersion in PRP at magnification 
of 500x, B) PCL after 60 min of immersion in PRP at magnification of 500x. C) Glass slide after 60 
min of immersion in PRP (magnification of 2000x), D) PCL after 60 min of immersion in PRP 
(magnification of 2000x). 
 
The micrographs shown in Figure 4-3 are representative pictures of the dispersion of 
platelets adhered onto the PCL films and glass slides. It was visibly clear that there 
were more platelets attached onto PCL films as compared to glass in a widespread and 
uniform fashion. At higher magnification, the platelets adhered onto the PCL films 
were noted to have a higher level of activation (spreading stage versus spread-dendritic 
stage) with developed pseudopod-like structure projections. The platelets also had 
extensive fibrin networks extending to surrounding areas similar to that observed in 
glass. Therefore, this shows that PCL film is capable of allowing conducive platelet 
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4.2.1.3. Results from thromboelastography 
 
 
Figure 4-4. Sample plot from TEG of the various samples (glass, PCL and blank). 
 
 
A sample of the TEG plots for the various materials was as shown in Figure 4-4. 
Results for different parameters as a measure of the clotting kinetics were collected as 
shown below.  
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Figure 4-5. Reaction time for initial fibrin to be formed 
 
 
For Figure 4-5, it was observed that the time for initial fibrin to be formed was 
statistically significantly higher for the blank negative control as compared to the one 
in contact with PCL.  It was also observed that the glass positive control took 
significantly lesser amount of time to clot as compared to the blood that was in contact 
with PCL. This shows that although PCL was not as efficient in clotting blood, there 
was still significant blood clotting effect rendered. 
 
 
Figure 4-6. Time required to arrive at the designated level of clotting (20% maximum strength) 
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The time required to clot and achieve up to 20% of the maximum strength of the clot 
was shown in Figure 4-6. It was observed that the blank negative control took a 
significantly longer period of time to achieve the designated level of clotting as 
compared to the blood in contact with PCL. It was also observed that glass took a 
significantly shorter period of time to achieve the designated level of clotting as 
compared to PCL. This trend was similar to that obtained from the measurement of the 
previous parameter, R.  
 
 




The maximum amplitude measured in Figure 4-7 indicates the ultimate strength of the 
fibrin clot and thus indicative of the surface consumption of clotting proteins. In this 
case, it was observed that the negative control had a statistically significantly stronger 
fibrin clot as compared to both glass and PCL. Glass was also observed to have 
statistical significantly similar fibrin clot strength as PCL. This indicates that the fibrin 
clot formed after being in contact with PCL and glass were weaker in strength and 
suggests blood-material interactions with PCL surfaces, leading to consumption of 
clotting proteins. 
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Figure 4-8. Graph of clotting speed measured using TEG method 
  
 
The angle measured using TEG indicates the speed of clotting when blood was in 
contact with the material. Specifically, the larger the angle measured, the faster the 
speed of clotting. From Figure 4-8, it was observed that the negative control of blank 
and PCL film was statistically significantly slower in clotting blood as compared to 
glass cover slip. This thus indicates that the speed of clotting measured for PCL film is 
slower as compared to the positive control of glass.  
 
Taking into consideration all the parameters (K value, R value, Maximum amplitude 
and angle) obtained from TEG, PCL can be regarded as a material that can bring about 
blood clotting effects, despite being not as effective a haemostat as glass where contact 
activation aspect is concerned.  
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4.2.1.4. Results from blood clotting index assay 
 
Figure 4-9. Blood clotting index measurement for comparison of PCL and glass control. * 
indicates a statistical significance with p < 0.05. 
 
 
Statistical difference was observed between PCL and the positive control glass as 
shown in Figure 4-9. This implies that PCL did not capture as much erythrocytes in the 
clot formed on the surface as compared to glass, thus rendering higher number of free-
floating red blood cells and higher BCI. However, it was noted that PCL did produce a 
significant haemostatic effect as compared to negative control, which is represented by 
100% in BCI through the normalisation process.  
 
4.2.1.5. Conclusion 
As TEG and PA assay investigated different aspects of haemostasis, a clear depiction 
of the haemostatic property for PCL was obtained. From TEG, it was noted that PCL 
could not perform as well as glass in terms of contact activation of blood. It could not 
produce as fast a clotting speed, as short a reaction time for fibrin clot to form and as 
short a clotting time for 20% of maximum strength of clot. However, from another 
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aspect of PA, PCL was able attract and adhere significantly more amount of platelets 
as compared to glass and was of a comparable level of activation.  Through BCI 
analysis, PCL was also shown to have significant blood clotting capabilities. Therefore, 
this shows that PCL does have the potential to be used for haemostatic purposes, but 
more modification and enhancements (i.e. with the addition of TCP) are needed for it 
to perform optimally.  
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4.2.2. Influence of TCP on haemostatic properties 
It was hypothesized that with the addition of TCP to PCL, the blood clotting ability of 
the polymer would improve as calcium is an important component in the blood clotting 
cascade. The chemical effect produced by the surface calcium would then bring about 
enhanced blood clotting. It was also hypothesized that with the addition of TCP, the 
surface roughness of the PCL heat pressed films would increase thereby affecting the 
blood-material interaction and possibly cause more platelets to be adhered to the film. 
Therefore in order to isolate the effects rendered and study the effects independently, 
the various films (with different percentages of TCP incorporated) were coated with a 
nano-thin layer of gold. This was so as to mask the chemical effect produced by the 
varying TCP concentrations and similar set of tests were used to analyze the gold 
coated samples.  
 
Surface chemistry and topography are also known to have direct influence on the 
characteristics of the surface adsorbed protein layer, which in turn affect the initiation 
of coagulation, platelet activation, aggregation and adhesion [Brash 1991, dos Santos 
et al. 2008, Park et al. 2001, Pitt et al. 1986]. Thus in this section, we analyzed the 
effect of TCP addition by focusing on the platelet activity in terms of its activation 
levels and amount of platelets adhered onto the surface.  
 
4.2.2.1. Materials and methods 
PCL-TCP heat pressed films with varying amounts of TCP (PCL-0wt%TCP, PCL-
10wt%TCP, PCL-20wt%TCP and PCL-25wt%TCP) were tested in this study. Pure 
PCL (PCL-0wt%TCP) was used as a negative control.  
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The blood collection and preparation methods for PRP were as stated previously. SEM 
was also used to image the surface of the specimens after immersion in PRP. Each of 
the micrographs (magnification of 750x) were then processed by outlining, coloring 
and expressing the area covered by the platelets as a percentage of the total area of the 
image for quantification purposes (as shown in Fig 4-10). The representative images 
(magnification of 4500x) were also evaluated for the level of platelet activation as 
described by Ko et al  [Ko and Cooper 1993]. 
 
      
 
Figure 4-10. (A) Original SEM picture of PCL-TCP specimen. (B) Processed SEM picture with 
platelet covered areas in red pixels. 
 
 
In order to mask the effects of TCP addition to the surface chemistry of the PCL-TCP 
films, without affecting the micro-scaled topographical changes brought about by the 
different percentages of TCP incorporation, the samples were gold sputtered with 
JEOL JFC-1200 Fine Coater machine at pressure of 10 Pa, 20 mA for 90 s in argon gas. 
This yields a gold coating thickness of 30.6nm which is sufficient to mask the surface 
chemistry effect while preserving surface topography [dos Santos et al. 2008].  
 
A B 
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Data points in this portion are expressed as means ± standard deviations. Differences 
between the means were analyzed for statistical significance using Student’s unpaired 
t-test or one-way ANOVA with post hoc Scheffe test . P values <0.05 were considered 
to be significant. 
 





Figure 4-11. SEM micrographs of morphology of platelets adhered onto A)PCL film B) PCL-
10%TCP film C)PCL-20%TCP film D)PCL-25% TCP film at magnification of 10%TCP film 
C)PCL-20%TCP film D)PCL-25% TCP film at magnification of 4500x 
A B 
C D 
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Figure 4-12. Percentage of area covered by platelets when viewed under x750 magnification. * 
indicates a statistical significance with the 20%TCP group with p < 0.05. 
 
 
The platelets adhered onto the surfaces of the various films were observed to be in high 
levels of activation with late pseudopodia, well spreading of hyaloplasm and some 
platelets had no distinct pseudopodia. There were no observable differences in the 
level of activations across the samples with different TCP incorporations (Figure 4-11).  
 
However, more informative observations were obtained after quantifying the area 
covered by the platelets for the different films. From Figure 4-12, it was observed that 
as the TCP concentration increased from 0% to 10%, the percentage area of the 
micrograph covered by adhered and aggregated platelets fell. The level rose 
significantly from 10% to 20% of TCP incorporation. It was also observed that the 
platelet coverage for 20%TCP and 25%TCP were not significantly different. This 
experiment was repeated using blood from 2 other donors and similar trends were 
observed.  
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This set of data represents both the chemical and surface topographical changes 
brought about by the various percentages of the incorporated TCP. The changes in the 
surface topography are as shown in Figure 4-13. With increasing TCP content, there 
was increased surface undulation but with decreasing scale of undulations. This could 
be due to TCP particles masking the effect of surface topography introduced by the 
heat press fabrication method. This theory also explains the decreasing scale of surface 





Figure 4-13. Representative images of the various percentages of TCP incorporation A) PCL films, 
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4.2.2.3. Results for platelet adhesion study of gold coated PCL-TCP with 





Figure 4-14. Representative micrographs of adhered platelets morphology on A) gold coated PCL 
film, B) gold coated PCL-10%TCP film, C) gold coated PCL-20%TCP film and D) gold coated 
PCL-25%TCP film at magnification of 4500x  
A B 
C D 
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Figure 4-15. Graph of percentage area covered by platelets onto PCL-TCP specimens with 
different percentages of TCP. 
 
 
All the platelets adhered onto the various films displayed highly activated stages of 
activation with late pseudopodial and evident hyaloplasm spreading (Figure 4-14). 
However, only PCL-0%TCP and PCL-20%TCP showed extensive network of fibrin in 
the clot. This was also evident from Figure 4-15, where gold coated PCL-0%TCP film 
showed most highly activated platelets and fibrin network. The area covered by 
platelets on pristine PCL films was also found to be statistically similar to that of the 
positive control, glass. An increasing trend in the percentage area covered by the 
adhered platelets was also observed with increasing TCP content from 10-25%.  
 
4.2.2.4. Discussions 
The delicate balance between the effect of increase in surface roughness and chemical 
effect was observed in this study. With 0% TCP incorporation, there was 
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comparatively lower surface roughness and this could have induced more platelet 
attraction and adhesion as observed in the results, even without the chemical effect 
from TCP (samples which were gold coated). However, when there was an increase in 
surface roughness, as in the case of 10%TCP-25%TCP, the amount of adhered 
platelets decreased. This could be due to the increase in surface roughness that 
prevented platelet adhesion and the incorporated TCP was too little to attract and 
adhere platelet by its chemical effect. This effect was seen with more TCP 
incorporation, the chemical effect of TCP set in and significantly increase the amount 
of adhered platelets at 20%TCP incorporation and possibly reached saturation at 
25%TCP (samples which were not gold coated).  Studies have shown that TCP had a 
strong attraction for serum proteins and integrins when compared with other types of 
implant materials [Kilpadi et al. 2001]. 
 
Looking at the chemical structure of TCP, it has a [(PO4)3-] site that binds to the [(-
NH3+)]  group in proteins and also a Ca2+ site that binds to (-COO-) site of proteins 
[Luo and Andrade 1998]. In blood, fibrinogen that is a protein influencing platelet 
adhesion and activation has a net negative charge that can be readily bonded to the 
positive site of TCP via electrostatic interactions [Chen et al. 1999, Luo and Andrade 
1998]. This does not apply only to charged proteins but also for neutral proteins as 
they can interact with amine and carboxylic groups when they dissociate at the right 
pH in aqueous solution [Chen et al. 1999, Franks 1988, Luo and Andrade 1998]. The 
pH of blood at 7.4 also allows TCP to exert a stronger effect on protein adsorption, 
platelet activation and adhesion that are mediated by absorbed proteins as more COO- 
groups that can bind proteins are available as compared to –NH3+ group at such a pH 
[Brash 1991, Franks 1988, Nygren et al. 1996, Pitt et al. 1986]. Furthermore, calcium 
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ions which are important components in the blood coagulation cascade can also be 
attracted to by TCP (its [(PO4)3-] site). This then serves to concentrate the calcium ions 
present in blood plasma and draw them to the surface thus enhancing coagulation to 
take place [Somasundaran 1984, Vogler and Siedlecki 2009, Wassell et al. 1995]. 
However, the chemical effect introduced by TCP is only valid for those TCP particles 
present at the surface of the mesh and the same is believed for the FDM-formed 
meshes. Any additional incorporation of TCP that exceeds the surface saturated 
amount for the mesh surfaces will not be able to enhance clotting any further. Likewise, 
any additions of TCP amounts less than optimum will not result in much TCP particles 
present at the surface but rather entrapped within the bulk of the mesh and such a 
composition will not be able to produce much chemical effect that aid clotting. This 
may explain the similar PA results were observed for both PCL-20%TCP and PCL-
25%TCP. With the optimum amount of TCP concentration at 20%, TCP particles are 
ensured to be present at the surface by saturation within the bulk material. 
 
4.2.2.5. Conclusion 
From this set of experiment, we have observed that the effect of TCP increased the 
amount of adhered platelets in general. Although the surface roughness introduced by 
the addition of TCP caused a drop in the amount of platelets adhered, the chemical 
effect of this addition increased the amount of platelets adhered with high level of 
activation instead. This effect was more prominent as compared to that rendered by the 
changes in surface topography. Therefore, all in all, the enhancement of haemostasis 
was observed upon the addition of TCP to the PCL material forming the composite, 
thus validating its addition and incorporation at 20%.   
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4.3. Influence of mesh architecture 
The electrospun PCL nanofibers (nano scale fibers), FDM-formed PCL mesh (micro 
scale rods) and heat pressed PCL film (macro scale) were tested to determine which of 
such scale of architecture is best suited for blood clotting applications. It has been 
hypothesized in this study that different scale of architecture was able to affect the 
clotting of blood due to its different surface area to volume ratio. 
  
4.3.1. Materials and methods 
Electrospun PCL nanofibers, FDM-formed PCL meshes and PCL heat pressed films 
were obtained by method previously described (Chapter 3). The specimens were then 
tested using qualitative PA evaluation, TEG method, and BCI assay. The PA, TEG and 
BCI methods were carried out as per previously described. Glass cover slips were used 
as positive control and blank as negative control in these sets of experiments as 
previously described. All the specimens tested in this experiment were of 12mm 
diameter and of similar gross area.  
 
Data points in this portion are expressed as means ± standard deviations. Differences 
between the means were analyzed for statistical significance using Student’s unpaired 
t-test or one-way ANOVA with post hoc Scheffe test. P values <0.05 were considered 
to be significant. 
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4.3.2. Results for platelet adhesion 
The representative SEM images of the specimens are shown in Figure 4-16. The extent 
of spreading of platelets were specifically noted in this assay and referenced to the 






Figure 4-16. Representative SEM micrographs of platelets attached on (a) glass (b) nanofibers (c) 
FDM-formed mesh (d) film at magnification of 2500x 
 
Extensive network of fibrin was observed for glass, nanofibers and FDM-formed mesh 
but not heat pressed film specimens. Platelets of rounder morphology (in the stage of 
spreading dentritics) were observed for nanofibers and film specimens. In contrast, 
fully spread platelet morphology was observed for both glass positive control and the 
FDM-formed mesh, which indicated a higher state of activation for platelets. This also 
a b 
c d 
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showed that FDM-formed meshes were comparable to the positive control in terms of 
the adhered platelets.  
 
From this, we have noted that platelets were more readily adhered, aggregated and 
activated by the micron scale architecture rendered by the FDM-formed mesh.   
 
4.3.3. Results from thromboelastography 
From the TEG assay, a few parameters for evaluation were obtained. Namely, the 
reaction time for fibrin formation (R-value), speed of clotting (angle alpha) and the 
overall clotting time (K value). 
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Figure 4-17. Reaction time for fibrin formation. Comparing PCL with different scales of 
architecture and different surface area to volume ratio. * indicates statistical significance between 
the two groups with p < 0.05. 
 
 
From the reaction time for fibrin formation recorded, it was noted that the reaction 
time needed for glass (positive control) and FDM-formed meshes were not statistically 
different using the student t-test (Figure 4-17). Furthermore, it was noted that the 
nanofibers and film took a significantly longer time to form fibrin when compared to 
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Figure 4-18. Comparing the speed of clotting of PCL with 3 different scales of architectures and 
different surface area to volume ratio. * indicates statistical significance between the two groups 
with p < 0.05. 
 
 
The gradient of the TEG curve, represented by the clotting angle alpha, is an indication 
of the speed of clot formation following initiation. From Figure 4-18, it was noted that 
the clotting speed of nanofibers were significantly slower than glass. Also, it was 
observed that both the FDM-formed and film specimens had comparable clotting speed 
to the positive control glass.  
* 
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Figure 4-19. Overall clotting time as depicted by K value. Comparing PCL with different scales of 
architecture and different surface area to volume ratio. * indicates a statistical significance 
between the two groups with p < 0.05. 
 
 
From Figure 4-19, it was observed that there were no statistical significant differences 
between glass, nanofibers and the FDM-formed mesh. It was however noted that film 
specimens took a significantly longer time to induce clotting. 
 
** 
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Figure 4-20. Maximum amplitude of TEG plot, that is indicative of the ultimate strength of the 
fibrin clot as an indication of surface consumption of clotting proteins. 
 
 
The maximum amplitude measured in Figure 4-20 indicates that there was no 
statistical significant difference between the various specimens tested. This could also 
imply that the clot strength formed by the various specimens were similar.  
 
These results demonstrate that all test surfaces induced contact activation of the blood 
coagulation cascade to varying degrees. It was observed that the FDM-formed group 
was the most highly activating, comparable to that of glass with the shortest time taken 
for clot initiation and most rapid clot formation. PCL heat pressed films, on the other 
hand took a significantly longer time for overall clotting. PCL nanofibers were 
observed to take significantly longer time for fibrin formation and the slower overall 
speed of clotting as compared to positive control. Hence FDM-formed mesh with 
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micro-scaled architecture was the most promising in aiding the blood clotting process 
with regards to contact activation.  
 
4.3.4. Blood clotting index assay 
 
Figure 4-21. Blood clotting index measurement for comparison of different architectures 
 
No statistical significance was observed between the BCI of the different architectures 
(Figure 4-21).  This could be due to the low sensitivity of the BCI assay, not being able 
to pick up the small difference contributed by the different architectures.  
 
4.3.5. Discussion 
The results from TEG and platelet adhesion assays have shown that FDM-formed 
meshes were comparable to glass in terms of contact activation and capable of readily 
attracting and adhering platelets by its micron scale architecture. This finding is 
Chapter 4: Haemostatic Properties 
 
 Page | 75 
comparable with several studies, where more platelets and proteins were adhered onto 
micron range architecture [Caterina et al. 2008, Koc et al. 2008, Koh et al. 2010]. 
Similarly, platelets were also found to not adhere as readily when surface topographies 
consist mainly of submicron features  [Koh et al. 2010]. 
 
4.3.6. Conclusion 
Taking the contact activation, platelet adhesion and blood clotting index into 
consideration, FDM-formed meshes with micro-scaled architecture have the largest 
potential to be comparable to the positive control, glass. This was due to the blood cell 
components responding only to micro-scaled architectures and not submicron or 
macro-scaled architectures. Thus, the use of FDM-formed mesh for this purpose is 
justified.   
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Chapter 5 . Antimicrobial Properties 
5.1. Introduction 
For this part of the thesis, the antimicrobial properties and evaluations will be reported. 
PCL-20%TCP FDM-formed mesh incorporated with various percentages of 
gentamicin sulphate (GS) were fabricated and evaluated in vitro for its efficacy against 
gram positive and gram negative bacteria, elution efficiency and cytotoxicity using the 
dermal fibroblast cells.  The specimens tested were summarized in Table 5-1. The 
appropriate GS incorporation concentration was then identified and used for further 
testing in vivo using a mouse full thickness infected wound model which will be 
reported in the next chapter.  
 
Table 5-1. Summary of Specimens tested for the determination of appropriate GS concentration 
Specimens Tested TCP content GS content Abbreviation 
PCL-20%TCP-0%GS 20% 0% PT0 
PCL-20%TCP-5%GS 20% 5% PT5 
PCL-20%TCP-15%GS 20% 15% PT15 
PCL-20%TCP-25%GS 20% 25% PT25 
 
 
It was also of interest to study the effect of TCP addition to the mesh and the release 
kinetics of incorporated drug. It has been previously reported by our group that with 
the addition of TCP to the PCL mesh, the loading efficiency and elution of rhBMP-2 
will be affected [Rai et al. 2005]. However, this relationship has yet to be investigated 
for the case of a low molecular weight, water soluble drug. Thus, in this chapter this 
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phenomenon will be reported for the case of GS elution (15 wt% incorporation) using 
PCL-TCP FDM-formed mesh with different TCP content. 
 
The samples tested for the drug elution assessments are described as follows:  
 
Table 5-2. Summary of the specimens tested in the investigation of TCP influence on GS elution 
Specimen Tested TCP content (wt%) GS Content (wt%) 
PCL-0%TCP-15%GS 0% 15% 
PCL-10%TCP-15%GS 10% 15% 
PCL-20%TCP-15%GS 20% 15% 
 
 
5.2. Materials and Methods 
5.2.1. Elution Profile 
The drug elution assay was adapted from report by Aviv et al. [Aviv et al. 2007]. 
FDM-formed mesh samples were immersed in 1.5 ml phosphate buffer saline (PBS) 
containing 0.05%w/v of sodium azide at 370C. The meshes were then removed and 
added into new vials of similar solution (n = 5) at the various time points of 0, 0.5, 2, 
3.5, 5, 6, 24, 48, 72, 96, 120 and 168 hours (up to 4 weeks for some parts of the 
experiment). The aliquots at various time points were frozen down to -800C for storage 
before analysis.  
 
For spectrophotometry analysis, an equal amount of O-phthaldiadehyde reagent (2.5 g 
of o-phthaldiadehyde, 62.5 ml of methanol and 3 ml of 2-hydroxy-ehtylmercaptan and 
560 ml of 0.04 M sodium borate in distilled water) and isopropanol were added to the 
Chapter 5: Antibacterial Properties 
 
 Page | 79 
aliquots and incubated in the dark for 45 min at room temperature. Absorbance at 332 
nm was measured with blank O-phthaldiadehyde and isopropanol as control. All 
readings were done in duplicates. The amount of GS was then calculated from a 
calibration curve generated with GS solutions of known concentrations (R-square = 
0.9994). 
 
5.2.2. Antimicrobial efficacy 
Time kill assays adapted from previous studies [Fraser et al. 2004, Ip et al. 2006] were 
conducted as follows. Staphylococcus aureus (S.a; ATCC25923) or Pseudomonas 
aeruginosa (P.a; ATCC27853) were prepared from tryptic soy broth (TSB) (Oxoid Ltd, 
Basingstoke, Hampshire, England) and concentration adjusted to 1x106 CFU/ml, based 
on 0.5 McFarland standards. Samples were then added to the bacterial broth culture, 
with untreated vials as growth control (n=3). The vials were then incubated at 350C 
with constant agitation. 50 µl of bacterial broth were aliquoted from each vial at 0, 30 
min, 2, 4, 24, 48 hours, and plated after serial dilution to enumerate the number of 
surviving colonies following incubation for 24h at 37°C. Counts were used to establish 
the number of CFU per ml of TSB. Reinoculations of the bacterial broth culture of 1 x 
106 CFU/ml were carried out at 24 hours and 48 hours. 
 
5.2.3. Cytotoxicity Assay 
Cytotoxicity of the PT0, PT5, PT15, PT25 were evaluated according to ISO 10993 
guidelines and with adaptation from Marques et al. and Burd et al.  [Burd et al. 2007, 
Marques et al. 2002]. Briefly, 8 x 104 human dermal fibroblast cells cultured in 
antibiotic-free high glucose Dulbecco modified eagle medium (DMEM) with L-
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glutamine and sodium pyruvate (Gibco), supplemented with 10% Fetal Bovine Serum 
(DMEM-FBS) were seeded to each well of a 12-well plate. The cells were allowed to 
adhere for 24 hours before the aseptically prepared samples were added. 
  
After 24, 48 and 72 hours, WST-1 Cell Proliferation Reagent (Roche Molecular 
Biochemicals) was used to study cell viability according to manufacturer’s instructions. 
Cell viability results for the different sample groups relative to the control group (PT0, 
cells in contact with PCL-20%TCP scaffolds without GS loaded) was obtained at each 
time point. 
 
5.2.4. Statistical Analysis 
Data points in this portion are expressed as means ± standard deviations. Differences 
between the means were analyzed for statistical significance using Student’s unpaired 
t-test or one-way ANOVA with post hoc Scheffe test. P values <0.05 were considered 
to be significant. 
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5.3. Results and Discussion 
5.3.1. Evaluation of appropriate antimicrobial incorporation  
5.3.1.1. Elution Profile 
 
Figure 5-1. Cumulative Elution Profile of 5wt%, 15wt% and 25wt% GS incorporated PCL-TCP 
mesh (in terms of percentage of the maximum possible theoretical GS concentration). The 
maximum theoretical concentration of GS for the 5wt%, 15wt% and 25wt% meshes are 290µg/ml, 
840µg/ml and 1400 µg/ml 
 
 
Figure 5-1 shows the cumulative elution profile of GS released from PT5, PT15 and 
PT25 scaffolds. All 3 groups demonstrated similar release profile over the study period. 
Within 168 hours, PT15 group achieved maximum release of 93% whereas the PT5 
and PT25 group released 80.2% and 86.1% respectively. All the curves follow a 
logarithmic release profile with R-squared values of 0.992, 0.9651, and 0.9513 for the 
PT5, PT15 and PT25 respectively. 
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5.3.1.2. Antimicrobial Efficacy 
 
Figure 5-2. Graph of log reduction assay for Pseudomonas aeruginosa. At the 24th and 48th hour, 
reinnoculation of approximately 106 bacteria was introduced and all groups produced similar 
results in both instances. 
 
 
Figure 5-3. Graph of Staphylococcus aureus count for the log reduction assay whereby the effect of 
the eluted GS was evaluated against Staphylococcus aureus. For the three groups, similar results 
were produced when reinoculated at the 24th hour. 
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Results from the log reduction assays are shown in Figure 5-2 (P.a) and Figure 5-3 
(S.a). It was observed that there was a general trend of 7-log reduction in the number 
of recoverable P.a and S.a from the original 1x106 cfu/ml of respective bacteria within 
the first 2 hours. It was also observed that within the first 24 hours for both bacteria 
types, PT25 group produced the largest reduction in bacteria number followed by PT15 
and PT5 groups. Upon reinnoculation of 1x106 cfu/ml bacteria at the 24th hour, a 
general trend of 6-log reduction was observed for both S.a and P.a. The reinnoculation 
at the 48th hour of the similar concentration of bacteria also yielded same results.  
 
5.3.1.3. Cytotoxicity Assay 
 
Figure 5-4. Cell viability assay using WST-1 assay. This was to evaluate any effects which the 
release of GS would have on cell growth 
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The cell viability when compared to growth control (PT0) was as shown in Figure 5-4. 
A general increasing trend of percentage cell viability with time was observed for PT0, 
PT5 and PT15 groups. For PT25 group, at the 48 hours and 72 hours time points, cell 
viability was significantly lower than PT0 (p<0.001), PT5(p<0.001) and PT15 groups 
(p<0.01), indicating that the GS dosage had adverse effects on cell viability. 
 
5.3.1.4. Discussion 
Interestingly, the high percentage cumulative release of GS from PCL-TCP scaffolds 
observed in our study differed from that observed in Miyai et al. as they detected a 
release of approximately 55% of the total incorporated antibiotic release throughout 
the 8 weeks study [Miyai et al. 2008]. From our in vitro studies, it was noted, on the 
contrary, that a high percentage (93%) of incorporated GS was released from the PT15 
mesh within 168 hours. This difference could be attributed to the difference in 
fabrication method, whereby our mesh architecture had a higher specific surface area 
thus enhancing the speed of diffusion of GS. On the other hand, the antibiotic, 
gatifloxacine, incorporated from Miyai et al. was of a lower molecular weight as 
compared to GS , thus with the diffusion theory in mind, one would expect the elution 
of gatifloxacine to be faster due to its lower molecular weight.  However, from this 
study, we have discovered that the reverse was true. This could be due to the more 
prominent effect of specific surface area of mesh/scaffold used for delivery. Generally, 
with a higher specific surface area for diffusion, a faster diffusion rate and elution 
profile would be expected [Kim et al. 2007]. In our study, the mesh used had a specific 
higher surface area due to its unique fabrication process of FDM as compared to that 
from Miyai et al. Thus in this light, a change in the specific surface area could heavily 
influence and alter a drug’s elution profile.  
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The burst release of GS during the first 24 hours observed in this study also differed 
from that observed by Miyai et al. (slow controlled release of antibiotics). This elution 
profile observed was considered a safe release profile as it featured a short duration of 
antibiotic release after which no antibiotic was further released to prevent sub-
inhibitory GS concentration that could bring about resistant strains [van de Belt et al. 
1999]. The need for a short term drug releasing platform was also often overlooked. 
Many drugs in the market need to be administered at different rates, especially for 
those to be used at the start of an infected wound treatment, whereby an initial burst 
release is essential in providing immediate relief followed by a diminishing need for 
drug [Setterstrom et al. 1984]. The burst release portion for PT5, PT15 and PT25 mesh 
should then be sufficient for prophylactic therapy  be it in surgical/implant or wound 
site [Stallmann et al. 2006]. 
 
It was also noted that 7%-19.8% of gentamicin sulfate were not eluted during the test 
period. This could be due to the drugs being trapped deep within the structure of the 
mesh and would most probably be released upon eventual degradation of the FDM-
formed PCL-TCP-GS mesh. 
 
Despite being highly efficient in eliminating bacteria and providing sustained 
protection against repeated inoculation of P.a and S.a, the PT5 and PT15 scaffold was 
tested to be non-cytotoxic. Although it was observed that bacterial reduction relates 
directly to the concentration of GS, cytotoxicity results revealed that compositions 
higher than 15wt% of GS adversely affected the cell viability, thereby putting a limit to 
the feasible concentration of GS that could be used. PT15 was thus selected and 
evaluated in the mice model subsequently.   
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5.3.1.5. Summary 
The GS loaded PCL-TCP haemostatic mesh with effective localized release using the 
solvent-free antibiotic delivery system was evaluated using the in vitro study. Both 
PT5 and PT25 scaffolds were not selected for the in vivo testing due to the inadequate 
bacteria elimination ability and possibly toxic levels of incorporation leading to the 
decrease in cell viability respectively.  The chosen PT15 scaffold was able to 
efficiently eliminate both gram-positive and gram-negative bacteria within 2 hours and 
had good biocompatibility with human dermal fibroblasts cells. 
 
5.3.2. Evaluation of TCP influence on drug elution 
To evaluate the influence of TCP on the elution of GS, FDM-formed meshes with 
different percentage of TCP incorporation were tested. 15 wt% GS was standardized 
through the specimens used in this evaluation. 
 
5.3.2.1. Materials and Methods 
Elution profiling was done as per previously described using the specimens listed in 
Table 5-2.  
 
5.3.2.2. Results and Discussion 
The elution profile of GS from the haemostatic mesh with different TCP contents were 
as shown in Figure 5-5 below.  
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It was observed that FDM-formed mesh with 20 wt% TCP incorporated had the largest 
burst release of GS for the first 24 hours. This was then followed by another small 
wave of release 1 week later. The burst amount of GS eluted was noted to increase 
with increasing percentage incorporation of TCP. This trend could be due to the 
increase in hydrophilicity of the mesh upon addition of TCP [Rai et al. 2005]. With the 
increase in hydrophilicity, the water soluble GS would then be able to elute freely and 
diffuse out of the mesh more efficiently due to the increased water penetration. This 
was especially vital for the GS loaded haemostatic mesh as elution via polymeric 
matrix degradation would be by no means useful for this application due to the slow 
degradation rate of PCL.  
 
Chapter 5: Antibacterial Properties 
 
 Page | 88 
5.3.2.3. Summary 
In summary, it is clear that with increased incorporation of TCP, there will be an 
increase in the elution of incorporated drugs, specifically the water soluble drugs. 
Therefore, it is possible to customize and design drug release profile by simply 
altering the percentage of TCP and consequently the mesh’s hydrophilicity.  
 
5.4. Conclusion 
The GS loaded PCL-TCP haemostatic mesh was evaluated for its optimal GS 
incorporation and TCP content in vitro. PCL-TCP with 15 wt% GS was found to be 
able to eliminate both gram-positive and gram-negative bacteria with 2 hours while not 
being cytotoxic, as tested using human dermal fibroblasts. The incorporation of 20 
wt% TCP was also demonstrated to improve hydrophilicity of the mesh, which led to 
accelerated drug release kinetics. Such release profile was considered suitable for the 
application of a drug eluting haemostatic mesh. 
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Chapter 6 . Antimicrobial Properties- In vivo Study 
6.1. Introduction 
For this part of the study, an infected full thickness excisional wound mouse model 
was used to study the antimicrobial haemostatic mesh in vivo. Although the in vitro 
antimicrobial activities of the PCL-TCP meshes had been demonstrated previously, 
further evaluations in the infected wound model would be necessary. This was to 
ascertain if the antimicrobial properties were reduced due to the complex in vivo 
environment. It should thus be noted that only in an in vivo environment could the 
holistic efficacy of the antimicrobial haemostatic mesh and its interactions with the 
host wound healing processes be evaluated. 
 
In this chapter, the state of infection, tissue regeneration and wound healing were 
evaluated at different time points. To characterize wound infection, various assays 
were carried out including gross observations, wound tissue biopsy, planimetry wound 
area measurement, weight loss analysis, neutrophil count and histology using gram 
stains. Further assays were conducted to evaluate skin tissue regeneration and wound 
healing, including gross observations, planimetry wound area measurements and 
histology using Hematoxylin & Eosin (H&E) and Masson’s trichrome stains. 
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6.2. Materials and Methods 
6.2.1. Mouse full thickness wound model 
Male Balb/C mice of 7 weeks old (19-27 g) were used in this study. Mice were housed 
individually in sterile individually ventilated cages (IVC) to prevent other mice from 
disturbing the wound and the dressings. All mice were acclimatized for one week 
before the surgery. All handling, maintenance and protocols were in accordance to the 
Institutional Animal Care and Use Committee (Defence Science Organisation-IACUC 
& National University of Singapore-IACUC). 
  
The mice were divided into two groups: gauze control group, which was given sterile 
gauze (3 cm x 2 cm) only, and the treatment group which was given PT15 ( PCL-
20%TCP with 15 wt% GS) of similar dimensions to control group as the primary 
dressing, with sterile gauze as the secondary dressing. Eight mice were used per group 
per time point in this study. After anesthetizing with intraperitoneal injection of 
ketamine and xylazine, a 1.0 cm x 1.0 cm full thickness excisional wound up till the 
panniculus adiposus was then created on the back of each mouse. The wound area was 
measured using a transparent graph sheet prior to bacterial inoculation. Each wound 
was inoculated with 35 µl of Pseudomonas aeruginosa (P.a; ATCC 27853) suspension 
(109-1010 CFU/ml), diluted from overnight culture and bacteria number gauged from 
standard curve of optical density plotted against live bacteria [Mi et al. 2002]. The 
bacteria suspension was left on the wound for 30 min, after which the respective 
dressings were applied to the surgical site and secured with 3M™ Transpore™ 
surgical tape (3M, Singapore). At time points of 1, 7 and 14 days post-surgery, 
measurements of wound area and weight were carried out. The mice were then 
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sacrificed and dressing materials removed. Blood and biopsy of tissue samples were 
harvested for neutrophil count, histology and microbial analysis for both groups.  
 
6.2.2. Wound Closure Measurement 
The wound area was measured using a standard plannimetry method [Gopinath et al. 
2005, Kirker et al. 2002]. At defined time points, the wound area was measured using a 
transparent graph sheet and the percentage of wound contraction was then defined as: 
 
Percentage wound closure = (Ao-At)/Ao x 100 
Where Ao is the original wound area and At is the area of wound at the respective 
 harvesting time points [Gopinath et al. 2005, Kirker et al. 2002].  
 
Photographs of the wound healing patterns were taken for qualitative analysis 
[Noorjahan and Sastry 2004].  
 
6.2.3. Weight Measurement 
Weights of mice were recorded before the surgery with an electronic mass balance 
(accurate to 0.01 g) and again just prior to sacrifice. Percentage weight loss was 
calculated as follows: 
Percentage weight loss = (Wi – Wt)/Wi x 100 
Where Wi is the initial weight of the mice before the surgery and Wt is the weight of 
the animal at the various time points.  
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6.2.4. Bacteria Count 
Weighed biopsies of 6 mm diameter was obtained from the wound area using 6 mm 
biopsy punch (Zuellig Pharma, Singapore) and homogenized using homogenizer 
(Heidolph Diax 900) in 1 ml of PBS  with 1% Tween-80 (buffer solution) mixture, 
without the removal of wound exudates [Martineau and Shek 2006]. The undiluted 
homogenized mix was serially plated onto TS agar plates and colonies were scored 
after incubation at 37°C overnight.  
 
6.2.5. Neutrophil Count 
Neutrophil count was carried out using Cell-Dyn® 3700 (Abbott Diagnostics, IL, 
USA) hemostasis analyzer as a measure of inflammation at the respective time points. 
0.5 ml blood was obtained from each mouse via cardiac puncture after anesthesia and 
supplemented with anticoagulant citrate dextrose prior to analysis to prevent clotting.  
 
6.2.6. Histology 
Biopsies of the wound sites were obtained and fixed in formalin (10%) for histological 
studies. Tissue samples were embedded in paraffin, sectioned and stained with H&E 
for general analyses, Massons’ Trichrome for identifying the presence of collagen and 
Gram stain for the localization of bacteria in the wound tissue. Representative images 
were captured to facilitate evaluation of epidermal and dermal healing. 
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6.2.7. Statistical Analysis 
Data points in this portion were expressed as means ± standard deviations. Differences 
between the means were analyzed for statistical significance using Student’s unpaired 
t-test or one-way ANOVA with post hoc Scheffe test. P values < 0.05 were considered 
to be significant. 
 
6.3. Results  
6.3.1. Microbial Load Analysis 
 
Figure 6-1. Bacteria count from wound tissue biopsy at different time points for TG and CG. At 
all time points, CG and TG data were statistical significantly different (p < 0.05), TG: treatment 
group, CG: control group. 
 
 
The microbial load within the wound site at various time points for both control group 
and treatment group were as shown in Figure 6-1. It was observed that for both 
treatment group and control group, there was a general decreasing trend in bacteria 
count. For treatment group, the bacteria count at wound site day 1 post-surgery was 
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reduced to below detectable limits. Similarly, no apparent bacterial colony was found 
at the wound day 7 and day 14 post-surgery. However, for the control group, 106 CFU 
was still detected after 14 days post-surgery.  
 
6.3.2. Wound Closure Analysis 
 
Figure 6-2. Wound area reduction measured at Day1, 7 and 14 post-surgery for CG and TG. *p < 
0.05, *** p<0.001, TG: treatment group, CG: control group. 
 
 
Gradual reduction in wound area was seen in both treatment group and control group 
over 14 days (Figure 6-2,). It was observed that at day 7 and day 14, the wound area of 
treatment group was significantly smaller than that of control group (2.28 and 1.58 
times smaller respectively, with p = 0.0007 and 0.0004 respectively). Treatment group 
at day 14 was noted to have achieved 94.2% wound area reduction, while control 
group only achieved 59.5% wound area reduction. 
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6.3.3. Weight Measurement Analysis 
 
Figure 6-3. Percentage of average weight loss recorded at different time point after the surgery 
and application of the wound dressing scaffold. Both * and ** indicates a statistical significance 
between the two groups with p < 0.05, TG: treatment group, CG: control group. 
 
 
In both treatment and control groups, mice showed weight loss and signs of bacterial 
infections (Figure 6-3). However on day 14, mice from treatment group experienced 
significantly higher weight gain while mice from control group continued with 
decrease in weight (treatment group: 5.5% weight gain, control group: 7.2% weight 
loss; p=0.0279), which implicate the better recovery from bacterial infection in 
treatment group compared to control group.  
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6.3.4. Neutrophil Count 
 
Figure 6- 4. Neutrophil count results indicate the overall infection level of mice from both TG and 
CG. * p < 0.05, TG: treatment group, CG: control group. 
 
 
The level of overall infections was measured by neutrophil count as represented in 
Figure 6-4. Neutrophil count of the mice in treatment group and control group peaked 
on day 1 post-surgery and decreased with time, with the exception of control group. 
For treatment group, neutrophil percentages decreased significantly on day 7 (5.4 fold 
decrease, p=0.0005) and remained low at day 14. However, on the other hand, control 
group’s neutrophil percentage rebounded with a peak on day 14 following a significant 
drop (0.4 fold increase, p=0.0132) on day 7 from day 1. 
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6.3.5. Photographic Analysis 
 
Figure 6- 5. Photographs of the full thickness excisional wounds (1 cm x 1 cm) taken prior to 
harvesting, TG: treatment group, CG: control group. 
 
 
At day 1 post-surgery, no visible difference in wound appearance was observed 
between treatment group and control group (Figure 6-5). However at day 7, treatment 
group was noted to have scab formation at the wound site with some wound 
contraction, whereas control group was still inflamed. The scab formation was attained 
by control group only on day 14 post-surgery. By day 14, the wound of treatment 
group appeared almost completely healed, leaving a small scab that was falling off.  
 
CG TG 
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In addition, treatment group did not suffer from adhesion problem of the dressing to 
the wound, as by day 7, the wound had already started to dry up and the PT15 mesh 
was expelled from closure of wounds. On the other hand, the control group had gauze 
fibers integrated into the wound during the healing process, leading to difficulty in 





Figure 6- 6. Histology using Gram staining. Arrows pointing to the area where bacteria were 
observed. TG: treatment group, CG: control group. 
 
CG TG 
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Under the gram histological staining (Figure 6-6), rod-shaped bacteria were observed 
in the upper layer of the wound biopsy for control group at day 1 (as indicated by 
arrows) but not for treatment group. No bacteria were found for the samples in 
treatment group and control group of later time points.  
 
 
Figure 6- 7. Histology using Masson’s Trichrome staining. With arrow pointing to area with neo-
collagen deposition (light blue region), TG: treatment group, CG: control group. 
 
 
The wound tissue biopsy showed similar amount of collagen in both treatment group 
and control group at day 1 post-surgery using Massons’ Trichrome staining (Figure 6-
7). However at day 7, treatment group was observed to have more neo-collagen formed 
and deposited as shown by the light blue collagen in contrast with the original collagen 
CG TG 
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which was darker blue in color. At day 14, both groups showed structures similar to 
the epidermis layer of the skin but treatment group had a more organized structure with 




Figure 6- 8. Histology using Hematoxylin and Eosin staining. With arrow pointing to an area of 
neo-vascularisation, TG: treatment group, CG: control group. 
 
 
From the H&E stains (Figure 6-8), significantly more cells were seen in the upper 
layer of the wound for control group at day 1 and day 7. These cells could be 
inflammatory cells that respond to injury and inflammation. Comparing treatment 
group and control group, it was noted that treatment group had an earlier onset of re-
epithelisation. There was also more neo-vascularisation observed in treatment group at 
CG TG 
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day 7 indicated by the dispersion of red blood cells across the wound area (indicated 
by the arrows in Figure 6-8). By day 14, both treatment group and control group 
showed the dermal and epidermal layer structures. However, the structures observed 
for control group were comparatively less organized and less aligned along the tension 
line of skin. 
 
6.4. Discussion 
Treatment group was contrasted with the gauze control group so as to evaluate the 
efficacy of the eluted drugs from the delivery platform (15%GS loaded PCL-20%TCP 
haemostatic mesh) in the in vivo environment. From the in vivo study, the GS loaded 
mesh demonstrated the ability to combat high concentrations of bacteria within 1 day 
and maintained high antibiotic efficacy to beyond 14 days. The eluted amount and 
release profile was also verified to be non-cytotoxic in the mice model. In addition, to 
compare the efficiency of the mice’s inherent immune system with the released GS 
from the GS loaded mesh, no antibiotic was administered to control group and a 
relatively high concentration of bacteria was still observed after day 14. 
 
According to Haas’ report, the stage of inflammation starts soon after haemostasis and 
usually completes within 48 to 72 hours [Haas 1995]. During this period, neutrophils, 
monocytes, lymphocytes and plasma cells migrate to the wound site as triggered by 
mediators from injured cells and capillaries, activated platelets and cytokines 
[Strodtbeck 2001]. Thus, these 48 to 72 hours become a critical time window, which 
the release of antibiotics should be targeted to prevent wound from being chronic. An 
early prevention in the biofilm formation will also greatly benefit the healing of wound, 
due to the dramatic increase of up to 1000 times more antibiotic-resistance in bacteria 
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after bacteria have formed a biofilm [Ceri et al. 1999]. P.a has been widely 
documented to cause significant wound deterioration due to the production of tissue 
destroying enzymes, exo- and endo-toxins, through antiphagocytic and adherence 
mechanisms [Dow et al. 1999, Kingsley 2003]. Thus without a significant reduction of 
bacteria concentration in wound to sub-infective level promptly, delay in wound 
healing would be expected [Edwards and Harding 2004]. It was therefore essential to 
provide prompt administration of antibiotics at an effective dose such that effective 
wound healing could be achieved.  
 
This important requisite was achieved by the GS eluting haemostatic mesh as 
accelerated wound closure was effected for treatment group at day 7 post-surgery, with 
almost complete healing observed at day 14. This could be due to the elimination of 
bacteria in the wound followed by the mesh’s enhancement of myofibroblasts activities 
and the promotion of the proliferative phase of fibroblast for wound healing. Wound 
area reduction is controlled by specialized myofibroblasts found within the granulation 
tissue and the lack of wound closure often indicates an active wound infection [Moulin 
et al. 2000, Ong et al. 2008]. As for control group, the slow rate of wound closure 
could be due to the presence of bacteria, microorganisms and their metabolites which 
inhibited wound closure process and wound healing [Robson et al. 1994]. The 
photographic evaluation also clearly indicated a significantly faster wound healing in 
treatment group.  
 
Continued weight loss of the animals was often associated with infections. Therefore, 
the weight gained by the mice from treatment group for day 14 could be indicative that 
they were cleared of infections previously introduced. This was compared to control 
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group that had continued to exhibit weight loss at day 14. Similarly, the elevated levels 
of neutrophils served as an indicator of sepsis and infection [Shapiro et al. 2008, 
Steiling et al. 1999]. Although neutrophils were one of the first to arrive at the injury 
site, it would disappear shortly unless the wound becomes infected [Mast 1999, 
Waldrop and Doughty 1991]. In this case, measuring the neutrohil count would be a 
good indication of general infection. The blood neutrophils percentage of treatment 
group was kept within the normal physiological conditions after day 7. Hence, 
indicating the cessation of the infection. However, for control group, the increase in 
neutrophil percentage could be a sign of secondary inflammation. This arose due to the 
presence of existing inflammation at the wound site, which depleted immune system, 
leading to opportunities for other infectious agents to bring about a secondary infection. 
From the elevated neutrophil levels in control group, it was also clear that the 
inoculated amount of P.a was of the infectious level. This rendered the animal’s self 
immune system ineffective in clearing the infection off their system within the 14 days 
of study since antibiotics were not supplemented. The immune system of treatment 
group on the other hand was supplemented by the GS incorporated mesh, enabling the 
group to fight the infectious level of P.a while preventing secondary infection from 
occurring.  
 
Histological analysis using gram stain showed that bacteria were only detected in 
control group at day 1 time point. This could be due to gram staining being a 
comparatively less sensitive method of analysis as compared to tissue biopsy. Day 14 
data from both Masson’s trichrome and H&E staining showed that treatment group had 
a more organized and aligned collagen structure, which was typical of native tissues; 
illustrating a faster healing rate for treatment group as compared to control group. With 
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the elimination of bacteria as early as day 1 post-surgery, the later stages of wound 
healing could then proceed effectively as if infectious agents were not present in 
wound. This aided the fast progression from inflammation phase of wound healing to 
the proliferative and repair phase whereby re-epithelization, neovascularisation and 
granulation could take place [Strodtbeck 2001, Waldrop and Doughty 1991]. This also 
coincided with the findings from the Masson’s trichrome and H&E staining.  
 
6.5. Conclusion 
From the in vivo analysis, PCL-20%TCP mesh with 15 wt% GS proved to be a highly 
effective local antibiotic delivery vehicle and exhibited exceptional ability to eliminate 
bacterial infections within 7 days. The wounds were also observed to heal more rapidly 
and re-epithelisation took place at an earlier time point as compared to control group 
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Chapter 7 . Conclusions and Recommendations 
7.1. Conclusions 
Many a times, tissue disruptions caused by external sources are often companied by 
haemorrhages and inflammation, which can inhibit or delay healthy tissue regeneration 
should these impairments not be controlled timely. The challenge hence lies in the 
development of a system that can intervene and restrain these tissue regeneration 
hurdles by providing haemostatic and antimicrobial solutions. The strategy developed 
in this research study involves the use of a haemostatic FDM-formed mesh made of 
PCL impregnated with 20 wt% TCP, and loaded with antimicrobial drugs that will be 
released timely within a short-term duration to allow inhibition of infection-causing 
microbes without affecting successive proliferation and reconstruction of native tissue.  
 
In this study, a series of in vitro and in vivo experiments were conducted to optimize 
and characterize this drug eluting haemostatic mesh, keeping in mind that the mesh 
was designed as a platform technology for a wide variety of applications such as a 
patch for surgical wound, scaffold for tissue engineering applications and wound 
dressing. Therefore, the optimizations and characterizations involved targeted specific 
attributes, which were the haemostatic and antimicrobial abilities, as depicted in a 
quick overview as follows: 
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1. Fabrication and optimization of the drug-eluting haemostatic FDM-formed 
mesh. 
In order to determine the optimal configuration and architecture of the mesh with best 
blood absorption potential, several types of FDM-formed PCL meshes with a variety 
of porosity and thickness parameters were produced and tested. Specifically, the 
configuration of the FDM-formed meshes were optimized first and used for all 
subsequent studies. FDM-formed meshes of varying porosities and thicknesses, 
ranging from 70% to 85% and 1 mm to 1.5 mm thickness respectively, were fabricated 
and subjected to blood absorption tests of varying immersion durations. PCL-TCP 
meshes were observed to absorb increasing amounts of blood with immersion duration, 
indicating that the FDM-formed PCL-TCP meshes could attract and absorb blood 
components. FDM-formed PCL-TCP meshes with 85% porosity and 1mm thickness 
was determined as the optimal structure within this study to absorb blood and bring 
about subsequent concentration of clotting factors within the mesh. Together with the 
fact that it was more pliable and hence suitable for practical applications, it was 
selected as the configuration for subsequent studies.  
 
2. Haemostatic properties due to PCL.  
From the material aspect, pure PCL was evaluated for its ability to trigger blood 
clotting via a series of PA, TEG and BCI assays. The heat pressed PCL films were 
used in these tests to compare with glass cover slips, which acted as positive control 
for these haemostatic assessments. It was indicated that PCL films could promote 
platelet adhesion, aggregation and activation more prominently than glass. Although in 
terms of contact activation, the time required for initial fibrin and clot formation was 
longer and clot formed was weaker in the PCL films as compared to glass, PCL film 
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was still regarded as a relevant haemostat as it was shown also to produce significant 
whole blood clotting when compared to negative control in BCI assay. 
 
3. Haemostatic properties due to TCP.  
With the addition of TCP to PCL, two aspects of the composite material were altered: 
the surface chemistry and surface topography. These surface aspects were found to 
affect the initiation of coagulation, platelet activation, aggregation and adhesion, hence 
proving the hypothesis that the addition of TCP could further enhance the haemostatic 
ability of PCL. To select the optimal amount of TCP to be added, 0 wt% to 25 wt% 
TCP were added to PCL and tested in the form of PCL-TCP heat pressed films against 
glass cover slips. This was once again done to rule out architectural variables. From 
the PA assay performed, it was observed that there was high levels of activation with 
late pseudopodia and well spreading of hyaloplasm as rendered by the PCL-TCP films 
with significantly higher platelet area coverage observed for the films with 20 wt% and 
25 wt%. Upon gold coating the PCL-TCP films, only the topographical effects due to 
inclusion of TCP was apparent. As such, highly activated platelets with extensive 
fibrin network was observed for the PCL-TCP films with 0 wt% TCP indicating that 
platelet attraction, adhesion and activation decreased with increased surface roughness. 
In the balance of the two aspects, PCL-TCP with 20 wt% TCP was selected as optimal. 
At this TCP concentration, the positive effects rendered by the chemical aspect tipped 
the negative topographical effects. Chemically, TCP provided the positive charge site 
to bind the net negatively charged fibrinogen, which is the protein influencing platelet 
adhesion and activation, while the phosphate site in TCP could attract and concentrate 
the calcium ions in blood to kick off the blood clotting cascade. Although further 
addition of TCP could aid increased platelet adhesion, it was not necessary as results 
Chapter 7: Conclusions and Recommendations 
 
 Page | 110 
showed negligible improvement with this addition. This was likely due to surface 
saturation of TCP at 20 wt% and further addition of TCP would only increase the bulk 
concentration and not the effective surface concentration.  
 
4. Haemostatic properties due to mesh architecture.  
Upon establishing the materials aspect in terms of its contribution to haemostasis, the 
architectural aspect was investigated next. FDM-formed meshes, optimized at 85% 
porosity and 1mm thickness, were compared with other architectures obtained via 
methods which included heat-pressing and electrospinning. Blood absorption assays, 
including PA, TEG and BCI, were performed on these architectures made with pure 
PCL to eliminate material contributions. It was clear that platelet adhesion and 
activation was supported by the micro-scale structure provided by the FDM-formed 
architecture, thereby supporting the hypothesis that meshes with micro-scaled 
architectures, similar to that of platelets, could bring about enhanced haemostatic 
effects. The speed of clotting, and time taken for fibrin and clot formation of the FDM-
formed architecture was also comparable with that of glass, indicating that the FDM-
formed architecture was the most promising architecture tested and was used for 
subsequent experiments.   
 
5. Antimicrobial properties of drug eluting haemostatic FDM-formed mesh.  
The ability for the drug eluting haemostatic mesh to inhibit microbial action was 
assessed. GS was used as the model drug to demonstrate the drug eluting ability of the 
PCL-TCP mesh. Since 20 wt% TCP incorporation was deemed to provide optimal 
haemostatic properties, it was selected to test for the optimal concentration for GS 
incorporation. 15 wt% GS was found to be optimal as it provided elimination of both 
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gram-positive and gram-negative bacteria within 2 hours with repeated bacterial 
inoculations at 24 and 48 hours, and bulk released 93% total GS loaded within 168 
hours, while being non-cytotoxic to native human dermal fibroblast cells. Since TCP 
could play a part in further altering the drug elution profile to that suitable for the 
application, optimization study on TCP content towards the drug elution profile of GS 
was performed. It was noted that burst release effect was more prominent with 
increasing TCP concentration due to the increasing hydrophilicity effected caused by 
TCP. As the drug eluting haemostatic mesh was designed to perform bulk elution of 
antimicrobial drugs at the inhibitory dose at its early application during the critical 
infectious period, with sharp reduction in its elution subsequently to allow tissue 
regeneration, the high TCP concentration of 20 wt% was selected for optimal drug 
elution in such applications. 20 wt% TCP was thus shown to be optimal for both drug 
elution and haemostatic purposes for the PCL-TCP FDM-formed mesh. 
 
The GS-loaded PCL-20%TCP haemostatic FDM-formed mesh was tested in vivo using 
a mouse full thickness skin wound model infected with Pseudomonas aeruginosa. It 
was observed that the mesh could reduce bacterial viability as non-detectable bacteria 
count was obtained from as early as day 1 post-surgery, with constant reduction in 
neutrophil count through the 14 day study. This led to subsequent accelerated wound 
closure and weight gain in the group treated with the GS eluting haemostatic mesh. 
Histological assessments of the regenerated tissue also indicated accelerated repair and 
regeneration with aligned and organized collagen structure and neo-vascularisation 
observed in the treated group by day 14. 
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In conclusion, the drug eluting haemostatic mesh was successfully developed using 
FDM-formed technique to produce micro-scaled architectures that were highly porous 
to allow effectively blood absorption and promoted platelet adhesion and activation. 
PCL-20%TCP was optimal in providing haemostatic functions through the unique 
chemical effects rendered by TCP and stimulated blood coagulation through platelet 
attachment and activation. The same TCP concentration could increase the mesh’s 
hydrophilicity to an extent that facilitated GS burst release to an elution profile suitable 
for early bacterial inhibition and subsequent tissue regeneration. This was apparent in 
the in vivo study using 15 wt% GS loaded haemostatic mesh. The drug eluting 
haemostatic mesh studied was thus shown to be a promising platform technology 
suitable for haemostatic and infection inhibitory applications. 
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7.2. Recommendations for future work 
At the current stage of research, there is still a lack in the detailed understanding of the 
pharmacokinetics and pharmacodynamics in vivo for this mode of antimicrobial 
impregnation and administration. It will be essential and beneficial to determine the 
biological half life, elimination rate constant, elimination rate and bioavailability of the 
incorporated GS. This is because studies have reported cases of nephrotoxicity 
associated with the use of GS, which is a well documented dose limiting factor in the 
use of aminoglycosides [Baciewicz et al. 2003, Rougier et al. 2004, Sweileh 2009]. GS 
and other aminoglycosides alike are not metabolized but eliminated by glomerular 
filtration, thus highlighting the possible accumulation in the kidney and the eventual 
importance of pharmacokinetics in the prevention of such symptoms [Martinez-
Salgado et al. 2007].  
 
Since the PCL-TCP FDM-formed mesh was developed to be a platform for delivery of 
drugs, we should look into incorporating other types of drugs into the mesh. This is 
especially so for antibiotics that have poor oral absorption, similar to that of GS, so 
that other routes of administration can be utilized rather than through intravenous and 
intramuscular means [Martinez-Salgado et al. 2007]. Apart from antibiotics with poor 
oral absorption, various different categories of drugs (for example, analgesics and anti-
inflammatory drugs) can also be incorporated. PCL-TCP FDM-formed mesh have 
proven in this study to be capable of eluting drugs at a fast pace to suit a variety of 
applications through diffusion, thus it will also be interesting to study the elution of 
drugs of different molecular weights to gain a more complete understanding of the true 
capability of this structure.  
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The uses and applications of the drug eluting haemostatic mesh have been envisioned 
to be well encompassing and varied, thus it will be good to implant the mesh in a load-
bearing application such as bone scaffold or surgical patch. This is so as to utilize other 
advantageous properties of the construct and tap on the benefit of it being able to 
degrade completely in vivo and remain biocompatible. In this study, we have only 
investigated the use of this mesh in an external wound environment as it enables a 
straight forward analysis of its antimicrobial efficacy.  
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